BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 2015;64:1972-84. [PMID: 26048673 DOI: 10.1136/gutjnl-2015-309809] [Cited by in Crossref: 487] [Cited by in F6Publishing: 449] [Article Influence: 69.6] [Reference Citation Analysis]
Number Citing Articles
1 Ji M, Hu K. Recent advances in the study of hepatitis B virus covalently closed circular DNA. Virol Sin. 2017;32:454-464. [PMID: 29280054 DOI: 10.1007/s12250-017-4009-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
2 Kayesh MEH, Hashem MA, Kohara M, Tsukiyama-kohara K. In vivo Delivery Tools for Clustered Regularly Interspaced Short Palindromic Repeat/Associated Protein 9-Mediated Inhibition of Hepatitis B Virus Infection: An Update. Front Microbiol 2022;13:953218. [DOI: 10.3389/fmicb.2022.953218] [Reference Citation Analysis]
3 Mu D, Yuan FC, Chen Y, Jiang XY, Yan L, Jiang LY, Gong JP, Zhang DZ, Ren H, Liao Y. Baseline value of intrahepatic HBV DNA over cccDNA predicts patient's response to interferon therapy. Sci Rep. 2017;7:5937. [PMID: 28725013 DOI: 10.1038/s41598-017-05242-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
4 Chen EQ, Feng S, Wang ML, Liang LB, Zhou LY, Du LY, Yan LB, Tao CM, Tang H. Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B. Sci Rep. 2017;7:173. [PMID: 28282964 DOI: 10.1038/s41598-017-00111-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
5 Lv W, Li T, Wang S, Wang H, Li X, Zhang S, Wang L, Xu Y, Wei W. The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer. Technol Cancer Res Treat 2021;20:15330338211045206. [PMID: 34605326 DOI: 10.1177/15330338211045206] [Reference Citation Analysis]
6 Nkongolo S, Nußbaum L, Lempp FA, Wodrich H, Urban S, Ni Y. The retinoic acid receptor (RAR) α-specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA. Antiviral Res 2019;168:146-55. [PMID: 31018112 DOI: 10.1016/j.antiviral.2019.04.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
7 Chen YL, Mo YQ, Zheng DH, Ma JD, Jing J, Dai L. Patients with Coexistence of Circulating Hepatitis B Surface Antigen and Its Antibody May Have a Strong Predisposition to Virus Reactivation During Immunosuppressive Therapy: A Hypothesis. Med Sci Monit 2017;23:5980-5. [PMID: 29248936 DOI: 10.12659/msm.905033] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Bassit L, Ono SK, Schinazi RF. Moving Fast Toward Hepatitis B Virus Elimination. Adv Exp Med Biol 2021;1322:115-38. [PMID: 34258739 DOI: 10.1007/978-981-16-0267-2_5] [Reference Citation Analysis]
9 Colledge D, Soppe S, Yuen L, Selleck L, Walsh R, Locarnini S, Warner N. Stop codons in the hepatitis B surface proteins are enriched during antiviral therapy and are associated with host cell apoptosis. Virology 2017;501:70-8. [DOI: 10.1016/j.virol.2016.11.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
10 van den Berg F, Limani SW, Mnyandu N, Maepa MB, Ely A, Arbuthnot P. Advances with RNAi-Based Therapy for Hepatitis B Virus Infection. Viruses 2020;12:E851. [PMID: 32759756 DOI: 10.3390/v12080851] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
11 Gao Y, Li Y, Meng Q, Zhang Z, Zhao P, Shang Q, Su M, Li T, Liu X, Zhuang H. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment? J Clin Microbiol. 2017;55:2972-2982. [PMID: 28747369 DOI: 10.1128/jcm.00760-17] [Cited by in Crossref: 32] [Cited by in F6Publishing: 10] [Article Influence: 6.4] [Reference Citation Analysis]
12 Minuk GY, Baruch Y. Hepatitis B viral infection of hepatic progenitor cells. Resolving unresolved questions? Med Hypotheses 2016;91:24-7. [PMID: 27142136 DOI: 10.1016/j.mehy.2016.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Hu J, Protzer U, Siddiqui A. Revisiting Hepatitis B Virus: Challenges of Curative Therapies. J Virol 2019;93:e01032-19. [PMID: 31375584 DOI: 10.1128/JVI.01032-19] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
14 Lai CL, Wong D, Ip P, Kopaniszen M, Seto WK, Fung J, Huang FY, Lee B, Cullaro G, Chong CK, Wu R, Cheng C, Yuen J, Ngai V, Yuen MF. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017;66:275-281. [PMID: 27639844 DOI: 10.1016/j.jhep.2016.08.022] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 14.5] [Reference Citation Analysis]
15 Roderburg C, Tacke F, Trautwein C. Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis. Visc Med. 2016;32:121-126. [PMID: 27413730 DOI: 10.1159/000444990] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
16 Wang ML, Deng R, Chen EQ, Tao CM, Liao J, Zhou TY, Wang J, Tang H. Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy. Clin Res Hepatol Gastroenterol 2019;43:301-9. [PMID: 30497844 DOI: 10.1016/j.clinre.2018.10.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
17 Kruse RL, Barzi M, Legras X, Pankowicz FP, Furey N, Liao L, Xu J, Bissig-Choisat B, Slagle BL, Bissig KD. A hepatitis B virus transgenic mouse model with a conditional, recombinant, episomal genome. JHEP Rep 2021;3:100252. [PMID: 33733079 DOI: 10.1016/j.jhepr.2021.100252] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Hui RW, Mak LY, Seto WK, Yuen MF. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: A spotlight on drugs at phase II clinical trials. Expert Opin Emerg Drugs 2022. [PMID: 35511483 DOI: 10.1080/14728214.2022.2074977] [Reference Citation Analysis]
19 Stevens CE, Toy P, Kamili S, Taylor PE, Tong MJ, Xia G, Vyas GN. Eradicating hepatitis B virus: The critical role of preventing perinatal transmission. Biologicals 2017;50:3-19. [DOI: 10.1016/j.biologicals.2017.08.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
20 Yamagiwa Y, Masaki N. Factors improving the utility of antiviral therapy for chronic hepatitis B: A nationwide multicenter study in Japan. Hepatol Res 2018;48:1069-80. [PMID: 29934990 DOI: 10.1111/hepr.13221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Nosaka T, Naito T, Matsuda H, Ohtani M, Hiramatsu K, Nemoto T, Nishizawa T, Okamoto H, Nakamoto Y. Molecular signature of hepatitis B virus regulation by interferon-γ in primary human hepatocytes. Hepatol Res 2020;50:292-302. [PMID: 31733138 DOI: 10.1111/hepr.13450] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Xu F, Song H, Xiao Q, Li N, Zhang H, Cheng G, Tan G. Type III interferon-induced CBFβ inhibits HBV replication by hijacking HBx. Cell Mol Immunol 2019;16:357-66. [PMID: 29523836 DOI: 10.1038/s41423-018-0006-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
23 Berke JM, Dehertogh P, Vergauwen K, Van Damme E, Mostmans W, Vandyck K, Pauwels F. Capsid Assembly Modulators Have a Dual Mechanism of Action in Primary Human Hepatocytes Infected with Hepatitis B Virus. Antimicrob Agents Chemother. 2017;61. [PMID: 28584155 DOI: 10.1128/aac.00560-17] [Cited by in Crossref: 61] [Cited by in F6Publishing: 28] [Article Influence: 12.2] [Reference Citation Analysis]
24 Birkus G, Snyder C, Jordan R, Kobayashi T, Dick R, Puscau V, Li L, Ramirez R, Willkom M, Morikawa Y, Delaney Iv WE, Schmitz U. Anti-HBV activity of retinoid drugs in vitro versus in vivo. Antiviral Res 2019;169:104538. [PMID: 31226346 DOI: 10.1016/j.antiviral.2019.104538] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
25 Yang F. Post-translational Modification Control of HBV Biological Processes. Front Microbiol 2018;9:2661. [PMID: 30443247 DOI: 10.3389/fmicb.2018.02661] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
26 Medhat A, Arzumanyan A, Feitelson MA. Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma. Oncotarget 2021;12:2421-33. [PMID: 34853663 DOI: 10.18632/oncotarget.28077] [Reference Citation Analysis]
27 Leowattana W, Leowattana T. Chronic hepatitis B: New potential therapeutic drugs target. World J Virol 2022; 11(1): 57-72 [DOI: 10.5501/wjv.v11.i1.57] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Yll M, Cortese MF, Guerrero-Murillo M, Orriols G, Gregori J, Casillas R, González C, Sopena S, Godoy C, Vila M, Tabernero D, Quer J, Rando A, Lopez-Martinez R, Esteban R, Riveiro-Barciela M, Buti M, Rodríguez-Frías F. Conservation and variability of hepatitis B core at different chronic hepatitis stages. World J Gastroenterol 2020; 26(20): 2584-2598 [PMID: 32523313 DOI: 10.3748/wjg.v26.i20.2584] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
29 Yao Y, Yang B, Cao H, Zhao K, Yuan Y, Chen Y, Zhang Z, Wang Y, Pei R, Chen J, Hu X, Zhou Y, Lu M, Wu C, Chen X. RBM24 stabilizes hepatitis B virus pregenomic RNA but inhibits core protein translation by targeting the terminal redundancy sequence. Emerg Microbes Infect 2018;7:86. [PMID: 29760415 DOI: 10.1038/s41426-018-0091-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
30 Asai A, Hirai S, Yokohama K, Nishikawa T, Nishikawa H, Higuchi K. Effect of an Electronic Alert System on Hepatitis B Virus Reactivation in Patients Receiving Immunosuppressive Drug Therapy. J Clin Med 2022;11:2446. [PMID: 35566572 DOI: 10.3390/jcm11092446] [Reference Citation Analysis]
31 Maravelia P, Frelin L, Ni Y, Caro Pérez N, Ahlén G, Jagya N, Verch G, Verhoye L, Pater L, Johansson M, Pasetto A, Meuleman P, Urban S, Sällberg M. Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections. J Infect Dis 2021;223:128-38. [PMID: 31994701 DOI: 10.1093/infdis/jiaa036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
32 Wing PA, Davenne T, Wettengel J, Lai AG, Zhuang X, Chakraborty A, D'Arienzo V, Kramer C, Ko C, Harris JM, Schreiner S, Higgs M, Roessler S, Parish JL, Protzer U, Balfe P, Rehwinkel J, McKeating JA. A dual role for SAMHD1 in regulating HBV cccDNA and RT-dependent particle genesis. Life Sci Alliance. 2019;2. [PMID: 30918010 DOI: 10.26508/lsa.201900355] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
33 Caviglia GP, Zorzi A, Rizzetto M, Mirandola M, Olivero A, Carolo G. Hepatitis B Virus Reactivation upon Immunosuppression: Is There a Role for Hepatitis B Core-Related Antigen in Patients with Immune-Escape Mutants? A Case Report. Diagnostics 2021;11:2185. [DOI: 10.3390/diagnostics11122185] [Reference Citation Analysis]
34 Eller C, Heydmann L, Colpitts CC, Verrier ER, Schuster C, Baumert TF. The functional role of sodium taurocholate cotransporting polypeptide NTCP in the life cycle of hepatitis B, C and D viruses. Cell Mol Life Sci. 2018;75:3895-3905. [PMID: 30097692 DOI: 10.1007/s00018-018-2892-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
35 García-garcía S, Caballero-garralda A, Tabernero D, Cortese MF, Gregori J, Rodriguez-algarra F, Quer J, Riveiro-barciela M, Homs M, Rando-segura A, Pacin-ruiz B, Vila M, Ferrer-costa R, Pumarola T, Buti M, Rodriguez-frias F. Hepatitis B Virus Variants with Multiple Insertions and/or Deletions in the X Open Reading Frame 3′ End: Common Members of Viral Quasispecies in Chronic Hepatitis B Patients. Biomedicines 2022;10:1194. [DOI: 10.3390/biomedicines10051194] [Reference Citation Analysis]
36 Akbar SM, Al-Mahtab M, Khan MS, Raihan R, Shrestha A. Immune therapy for hepatitis B. Ann Transl Med 2016;4:335. [PMID: 27761439 DOI: 10.21037/atm.2016.08.48] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
37 Wang G, Guan J, Khan NU, Li G, Shao J, Zhou Q, Xu L, Huang C, Deng J, Zhu H, Chen Z. Potential capacity of interferon-α to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus. Gut Pathog 2021;13:22. [PMID: 33845868 DOI: 10.1186/s13099-021-00421-9] [Reference Citation Analysis]
38 Bousali M, Papatheodoridis G, Paraskevis D, Karamitros T. Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma. Microorganisms 2021;9:1787. [PMID: 34442866 DOI: 10.3390/microorganisms9081787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Singh KP, Crane M, Audsley J, Avihingsanon A, Sasadeusz J, Lewin SR. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS 2017;31:2035-52. [PMID: 28692539 DOI: 10.1097/QAD.0000000000001574] [Cited by in Crossref: 120] [Cited by in F6Publishing: 71] [Article Influence: 24.0] [Reference Citation Analysis]
40 Li Y, Zhu C, Wang F, Zhu T, Li J, Liu S, Xiao F. Expression of Interferon Effector Gene SART1 Correlates with Interferon Treatment Response against Hepatitis B Infection. Mediators Inflamm 2016;2016:3894816. [PMID: 28077916 DOI: 10.1155/2016/3894816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
41 Sajidah ES, Lim K, Wong RW. How SARS-CoV-2 and Other Viruses Build an Invasion Route to Hijack the Host Nucleocytoplasmic Trafficking System. Cells 2021;10:1424. [PMID: 34200500 DOI: 10.3390/cells10061424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol 2016;64:S4-S16. [PMID: 27084035 DOI: 10.1016/j.jhep.2016.01.027] [Cited by in Crossref: 186] [Cited by in F6Publishing: 184] [Article Influence: 37.2] [Reference Citation Analysis]
43 Guo F, Xing L. RNA helicase A as co-factor for DNA viruses during replication. Virus Res 2021;291:198206. [PMID: 33132162 DOI: 10.1016/j.virusres.2020.198206] [Reference Citation Analysis]
44 Lin Y, Deng W, Pang J, Kemper T, Hu J, Yin J, Zhang J, Lu M. The microRNA-99 family modulates hepatitis B virus replication by promoting IGF-1R/PI3K/Akt/mTOR/ULK1 signaling-induced autophagy. Cell Microbiol. 2017;19. [PMID: 27886437 DOI: 10.1111/cmi.12709] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
45 Lin TC, Chiu YC, Chiu HC, Liu WC, Cheng PN, Chen CY, Chang TT, Wu IC. Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy. World J Gastroenterol 2018; 24(6): 725-736 [PMID: 29456411 DOI: 10.3748/wjg.v24.i6.725] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
46 Wang YX, Niklasch M, Liu T, Wang Y, Shi B, Yuan W, Baumert TF, Yuan Z, Tong S, Nassal M, Wen YM. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication. J Hepatol. 2020;72:865-876. [PMID: 31863794 DOI: 10.1016/j.jhep.2019.12.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
47 Yim HJ, Kim W, Ahn SH, Jung YK, Um SH, Sohn JH, Jang JY, Kim DJ, Park ES, Jin SY, Kim KH. Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients. J Gastroenterol Hepatol 2021. [PMID: 34653281 DOI: 10.1111/jgh.15710] [Reference Citation Analysis]
48 [DOI: 10.1101/2020.03.27.011841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Sa-Ngiamsuntorn K, Thongsri P, Pewkliang Y, Wongkajornsilp A, Kongsomboonchoke P, Suthivanich P, Borwornpinyo S, Hongeng S. An Immortalized Hepatocyte-like Cell Line (imHC) Accommodated Complete Viral Lifecycle, Viral Persistence Form, cccDNA and Eventual Spreading of a Clinically-Isolated HBV. Viruses 2019;11:E952. [PMID: 31623162 DOI: 10.3390/v11100952] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
50 Suslov A, Meier MA, Ketterer S, Wang X, Wieland S, Heim MH. Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity. J Hepatol 2021;74:794-800. [PMID: 33188905 DOI: 10.1016/j.jhep.2020.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
51 Li Y, He M, Gong R, Wang Z, Lu L, Peng S, Duan Z, Feng Y, Liu Y, Gao B. Forkhead O Transcription Factor 4 Restricts HBV Covalently Closed Circular DNA Transcription and HBV Replication through Genetic Downregulation of Hepatocyte Nuclear Factor 4 Alpha and Epigenetic Suppression of Covalently Closed Circular DNA via Interacting with Promyelocytic Leukemia Protein. J Virol 2022;:e0054622. [PMID: 35695580 DOI: 10.1128/jvi.00546-22] [Reference Citation Analysis]
52 Goyal A, Ribeiro RM, Perelson AS. The Role of Infected Cell Proliferation in the Clearance of Acute HBV Infection in Humans. Viruses 2017;9:E350. [PMID: 29156567 DOI: 10.3390/v9110350] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
53 Limothai U, Chuaypen N, Poovorawan K, Chotiyaputta W, Tanwandee T, Poovorawan Y, Tangkijvanich P. Reverse transcriptase droplet digital PCR vs reverse transcriptase quantitative real-time PCR for serum HBV RNA quantification. J Med Virol 2020. [PMID: 32219874 DOI: 10.1002/jmv.25792] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
54 Zeyen L, Prange R. Host Cell Rab GTPases in Hepatitis B Virus Infection. Front Cell Dev Biol 2018;6:154. [PMID: 30510928 DOI: 10.3389/fcell.2018.00154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
55 Dandri M. Epigenetic modulation in chronic hepatitis B virus infection. Semin Immunopathol 2020;42:173-85. [PMID: 32185454 DOI: 10.1007/s00281-020-00780-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
56 Durantel D. New treatments to reach functional cure: Virological approaches. Best Pract Res Clin Gastroenterol. 2017;31:329-336. [PMID: 28774415 DOI: 10.1016/j.bpg.2017.05.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
57 Li Y, He M, Wang Z, Duan Z, Guo Z, Wang Z, Gong R, Chu T, Cai J, Gao B. STING signaling activation inhibits HBV replication and attenuates the severity of liver injury and HBV-induced fibrosis. Cell Mol Immunol 2021. [PMID: 34811496 DOI: 10.1038/s41423-021-00801-w] [Reference Citation Analysis]
58 Brezgin S, Kostyusheva A, Bayurova E, Gordeychuk I, Isaguliants M, Goptar I, Nikiforova A, Smirnov V, Volchkova E, Glebe D, Kostyushev D, Chulanov V. Replenishment of Hepatitis B Virus cccDNA Pool Is Restricted by Baseline Expression of Host Restriction Factors In Vitro. Microorganisms 2019;7:E533. [PMID: 31698767 DOI: 10.3390/microorganisms7110533] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
59 Niller HH, Ay E, Banati F, Demcsák A, Takacs M, Minarovits J. Wild type HBx and truncated HBx: Pleiotropic regulators driving sequential genetic and epigenetic steps of hepatocarcinogenesis and progression of HBV-associated neoplasms. Rev Med Virol 2016;26:57-73. [PMID: 26593760 DOI: 10.1002/rmv.1864] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
60 Hu Y, Zhang H, Wu M, Liu J, Li X, Zhu X, Li C, Chen H, Liu C, Niu J, Ding Y. Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individuals. Expert Opin Investig Drugs 2021;30:263-9. [PMID: 33405993 DOI: 10.1080/13543784.2021.1873275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Datta S, Dasgupta D, Ghosh A, Ghosh S, Manna A, Datta S, Chatterjee M, Chowdhury A, Banerjee S. Oncogenic potential of hepatitis B virus subgenotype D1 surpasses D3: significance in the development of hepatocellular carcinoma. Carcinogenesis 2018;39:283-92. [PMID: 29228221 DOI: 10.1093/carcin/bgx145] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
62 Kostyushev D, Kostyusheva A, Brezgin S, Zarifyan D, Utkina A, Goptar I, Chulanov V. Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9. Sci Rep 2019;9:1847. [PMID: 30755668 DOI: 10.1038/s41598-019-38526-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
63 Qin Y, Yu H, Yuan S, Yang Z, Ren F, Wang Q, Li F, Ren J, Cheng S, Zhou Y, He X, Zhou H, Zhang Y, Tan M, Yang M, Zhang D, Wen X, Dong M, Zhang H, Liu J, Li Z, Chen Y, Huang A, Chen W, Chen J. KAT2A Promotes Hepatitis B Virus Transcription and Replication Through Epigenetic Regulation of cccDNA Minichromosome. Front Microbiol 2022;12:795388. [DOI: 10.3389/fmicb.2021.795388] [Reference Citation Analysis]
64 Lee HW, Choi Y, Lee AR, Yoon CH, Kim KH, Choi BS, Park YK. Hepatocyte Growth Factor-Dependent Antiviral Activity of Activated cdc42-Associated Kinase 1 Against Hepatitis B Virus. Front Microbiol 2021;12:800935. [PMID: 35003030 DOI: 10.3389/fmicb.2021.800935] [Reference Citation Analysis]
65 Caviglia GP, Armandi A, Rosso C, Ribaldone DG, Pellicano R, Fagoonee S. Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis. Diagnostics (Basel) 2021;11:187. [PMID: 33525443 DOI: 10.3390/diagnostics11020187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
66 Heger-Stevic J, Zimmermann P, Lecoq L, Böttcher B, Nassal M. Hepatitis B virus core protein phosphorylation: Identification of the SRPK1 target sites and impact of their occupancy on RNA binding and capsid structure. PLoS Pathog 2018;14:e1007488. [PMID: 30566530 DOI: 10.1371/journal.ppat.1007488] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
67 Chinnakannan SK, Cargill TN, Donnison TA, Ansari MA, Sebastian S, Lee LN, Hutchings C, Klenerman P, Maini MK, Evans T, Barnes E. The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV. Vaccines (Basel) 2020;8:E184. [PMID: 32295168 DOI: 10.3390/vaccines8020184] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
68 Wei L, Ploss A. Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation. Nat Microbiol. 2020;5:715-726. [PMID: 32152586 DOI: 10.1038/s41564-020-0678-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
69 Wang J, Yu Y, Li G, Shen C, Li J, Chen S, Zhang X, Zhu M, Zheng J, Song Z, Wu J, Shao L, Meng Z, Wang X, Huang Y, Zhang J, Qiu C, Zhang W. Natural history of serum HBV-RNA in chronic HBV infection. J Viral Hepat. 2018;25:1038-1047. [PMID: 29633430 DOI: 10.1111/jvh.12908] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
70 Li H, Yan L, Shi Y, Lv D, Shang J, Bai L, Tang H. Hepatitis B Virus Infection: Overview. Adv Exp Med Biol 2020;1179:1-16. [PMID: 31741331 DOI: 10.1007/978-981-13-9151-4_1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
71 Cacoub P, Asselah T. Hepatitis B Virus Infection and Extra-Hepatic Manifestations: A Systemic Disease. Am J Gastroenterol 2021. [PMID: 34913875 DOI: 10.14309/ajg.0000000000001575] [Reference Citation Analysis]
72 Lin TC, Liu WC, Hsu YH, Lin JJ, Chiu YC, Chiu HC, Cheng PN, Chen CY, Chang TT, Wu IC. Insulin Resistance Associated Disorders Pivoting Long-Term Hepatitis B Surface Antigen Decline During Entecavir Therapy. J Clin Med 2019;8:E1892. [PMID: 31698809 DOI: 10.3390/jcm8111892] [Reference Citation Analysis]
73 Guo F, Zhao Q, Sheraz M, Cheng J, Qi Y, Su Q, Cuconati A, Wei L, Du Y, Li W, Chang J, Guo JT. HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways. PLoS Pathog. 2017;13:e1006658. [PMID: 28945802 DOI: 10.1371/journal.ppat.1006658] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 10.8] [Reference Citation Analysis]
74 Moshkani S, Chiale C, Lang SM, Rose JK, Robek MD. A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B. J Virol 2019;93:e01586-18. [PMID: 30541859 DOI: 10.1128/JVI.01586-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
75 Fergusson JR, Wallace Z, Connolly MM, Woon AP, Suckling RJ, Hine DW, Barber C, Bunjobpol W, Choi BS, Crespillo S, Dembek M, Dieckmann N, Donoso J, Godinho LF, Grant T, Howe D, McCully ML, Perot C, Sarkar A, Seifert FU, Singh PK, Stegmann KA, Turner B, Verma A, Walker A, Leonard S, Maini MK, Wiederhold K, Dorrell L, Simmons R, Knox A. Immune-Mobilizing Monoclonal T Cell Receptors Mediate Specific and Rapid Elimination of Hepatitis B-Infected Cells. Hepatology 2020;72:1528-40. [PMID: 32770836 DOI: 10.1002/hep.31503] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
76 Yang L, Liu F, Tong X, Hoffmann D, Zuo J, Lu M. Treatment of Chronic Hepatitis B Virus Infection Using Small Molecule Modulators of Nucleocapsid Assembly: Recent Advances and Perspectives. ACS Infect Dis 2019;5:713-24. [PMID: 30896149 DOI: 10.1021/acsinfecdis.8b00337] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
77 Revill PA, Penicaud C, Brechot C, Zoulim F. Meeting the Challenge of Eliminating Chronic Hepatitis B Infection. Genes (Basel) 2019;10:E260. [PMID: 30939846 DOI: 10.3390/genes10040260] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
78 Muraleedharan A, Bupesh G. A short note on HBV infection. Bioinformation 2020;16:505-8. [PMID: 32994674 DOI: 10.6026/97320630016505] [Reference Citation Analysis]
79 Li G, Zhu Y, Shao D, Chang H, Zhang X, Zhou D, Gao Y, Lan K, Deng Q. Recombinant covalently closed circular DNA of hepatitis B virus induces long-term viral persistence with chronic hepatitis in a mouse model. Hepatology 2018;67:56-70. [PMID: 28749559 DOI: 10.1002/hep.29406] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
80 Chen E, Wang M, Tao Y, Wu D, Liao J, He M, Tang H. Serum HB crAg is better than HBV RNA and HB sAg in reflecting intrahepatic covalently closed circular DNA. J Viral Hepat 2019;26:586-95. [DOI: 10.1111/jvh.13061] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
81 Jiang B, Su R, Ren D, Zheng X, Cao Y, Mi Y, Wang F, Ma P. Evaluation of HBV serological markers in treatment-naïve HBV mono-infected patients and HBV-HIV co-infected patients. Virus Res 2020;290:198117. [PMID: 32800804 DOI: 10.1016/j.virusres.2020.198117] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Meier-Stephenson V, Badmalia MD, Mrozowich T, Lau KCK, Schultz SK, Gemmill DL, Osiowy C, van Marle G, Coffin CS, Patel TR. Identification and characterization of a G-quadruplex structure in the pre-core promoter region of hepatitis B virus covalently closed circular DNA. J Biol Chem 2021;296:100589. [PMID: 33774051 DOI: 10.1016/j.jbc.2021.100589] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Kong F, Li Q, Zhang F, Li X, You H, Pan X, Zheng K, Tang R. Sirtuins as Potential Therapeutic Targets for Hepatitis B Virus Infection. Front Med (Lausanne) 2021;8:751516. [PMID: 34708060 DOI: 10.3389/fmed.2021.751516] [Reference Citation Analysis]
84 Lok J, Agarwal K. Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. Viruses 2021;13:1333. [PMID: 34372539 DOI: 10.3390/v13071333] [Reference Citation Analysis]
85 Chen Y, Shen B, Zheng X, Long Q, Xia J, Huang Y, Cai X, Wang D, Chen J, Tang N, Huang A, Hu Y. DHX9 interacts with APOBEC3B and attenuates the anti-HBV effect of APOBEC3B. Emerg Microbes Infect 2020;9:366-77. [PMID: 32056513 DOI: 10.1080/22221751.2020.1725398] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
86 Flecken T, Meier MA, Skewes-Cox P, Barkan DT, Heim MH, Wieland SF, Holdorf MM. Mapping the Heterogeneity of Histone Modifications on Hepatitis B Virus DNA Using Liver Needle Biopsies Obtained from Chronically Infected Patients. J Virol 2019;93:e02036-18. [PMID: 30787147 DOI: 10.1128/JVI.02036-18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
87 Mitra B, Thapa RJ, Guo H, Block TM. Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B. Antiviral Res. 2018;158:185-198. [PMID: 30145242 DOI: 10.1016/j.antiviral.2018.08.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
88 Diab A, Foca A, Zoulim F, Durantel D, Andrisani O. The diverse functions of the hepatitis B core/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals. Antiviral Res. 2018;149:211-220. [PMID: 29183719 DOI: 10.1016/j.antiviral.2017.11.015] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 8.6] [Reference Citation Analysis]
89 Stadler D, Kächele M, Jones AN, Hess J, Urban C, Schneider J, Xia Y, Oswald A, Nebioglu F, Bester R, Lasitschka F, Ringelhan M, Ko C, Chou WM, Geerlof A, van de Klundert MA, Wettengel JM, Schirmacher P, Heikenwälder M, Schreiner S, Bartenschlager R, Pichlmair A, Sattler M, Unger K, Protzer U. Interferon-induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20. EMBO Rep 2021;22:e49568. [PMID: 33969602 DOI: 10.15252/embr.201949568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
90 Tu T, Budzinska MA, Shackel NA, Urban S. HBV DNA Integration: Molecular Mechanisms and Clinical Implications. Viruses. 2017;9. [PMID: 28394272 DOI: 10.3390/v9040075] [Cited by in Crossref: 140] [Cited by in F6Publishing: 132] [Article Influence: 28.0] [Reference Citation Analysis]
91 Matsuda S, Maekawa S, Komiyama Y, Nakakuki N, Muraoka M, Suzuki Y, Sato M, Tatsumi A, Miura M, Amemiya F, Shindo H, Takano S, Fukasawa M, Yamaguchi T, Nakayama Y, Inoue T, Sato T, Yamashita A, Moriishi K, Enomoto N. Deep sequencing analysis of serum hepatitis B virus-RNA during nucleot(s)ide analogue therapy. Hepatol Res 2021;51:39-50. [PMID: 32961003 DOI: 10.1111/hepr.13574] [Reference Citation Analysis]
92 Kim H, Ko C, Lee JY, Kim M. Current Progress in the Development of Hepatitis B Virus Capsid Assembly Modulators: Chemical Structure, Mode-of-Action and Efficacy. Molecules 2021;26:7420. [PMID: 34946502 DOI: 10.3390/molecules26247420] [Reference Citation Analysis]
93 Fernández I, Pascasio JM, Colmenero J; en nombre del grupo de trabajo para el VII consenso de la SETH., Autores participantes en el grupo de trabajo en representación de sus respectivos programas de trasplante hepático. Prophylaxis and treatment in liver transplantation. VII Consensus Document of the Spanish Society of Liver Transplantation. Gastroenterol Hepatol 2020;43:169-77. [PMID: 32094045 DOI: 10.1016/j.gastrohep.2019.11.005] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Liu Y, Maya S, Ploss A. Animal Models of Hepatitis B Virus Infection-Success, Challenges, and Future Directions. Viruses 2021;13:777. [PMID: 33924793 DOI: 10.3390/v13050777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Zeisel MB, Baumert TF. Hepatitis B virus: is a cure possible? Expert Rev Clin Pharmacol 2016;9:1129-30. [PMID: 27347775 DOI: 10.1080/17512433.2016.1206466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
96 Watanabe T, Hayashi S, Tanaka Y. Drug Discovery Study Aimed at a Functional Cure for HBV. Viruses 2022;14:1393. [DOI: 10.3390/v14071393] [Reference Citation Analysis]
97 Ma G, Lou B, Lv F, Zhao D, Chen H, Ye X, Chen Y. HBcrAg, pg RNA and HBsAg dynamically supervise the seroconversion of HBsAg with anti-viral therapy: "Loss of HBsAg" maybe not a good end-point of anti-viral therapy. Clin Chim Acta 2020;501:264-9. [PMID: 31730814 DOI: 10.1016/j.cca.2019.10.049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
98 Lee HW, Lee JS, Ahn SH. Hepatitis B Virus Cure: Targets and Future Therapies. Int J Mol Sci 2020;22:E213. [PMID: 33379331 DOI: 10.3390/ijms22010213] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
99 Mohd-Ismail NK, Lim Z, Gunaratne J, Tan YJ. Mapping the Interactions of HBV cccDNA with Host Factors. Int J Mol Sci. 2019;20. [PMID: 31480501 DOI: 10.3390/ijms20174276] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
100 Schreiner S, Nassal M. A Role for the Host DNA Damage Response in Hepatitis B Virus cccDNA Formation-and Beyond? Viruses 2017;9:E125. [PMID: 28531167 DOI: 10.3390/v9050125] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 9.6] [Reference Citation Analysis]
101 Chang S, Wang LH, Chen BS. Investigating Core Signaling Pathways of Hepatitis B Virus Pathogenesis for Biomarkers Identification and Drug Discovery via Systems Biology and Deep Learning Method. Biomedicines. 2020;8. [PMID: 32878239 DOI: 10.3390/biomedicines8090320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
102 Mahas A, Mahfouz M. Engineering virus resistance via CRISPR-Cas systems. Curr Opin Virol 2018;32:1-8. [PMID: 30005359 DOI: 10.1016/j.coviro.2018.06.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 6.5] [Reference Citation Analysis]
103 Hensel KO, Rendon JC, Navas MC, Rots MG, Postberg J. Virus-host interplay in hepatitis B virus infection and epigenetic treatment strategies. FEBS J. 2017;284:3550-3572. [PMID: 28457020 DOI: 10.1111/febs.14094] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
104 Hensel KO, Cantner F, Bangert F, Wirth S, Postberg J. Episomal HBV persistence within transcribed host nuclear chromatin compartments involves HBx. Epigenetics Chromatin 2018;11:34. [PMID: 29933745 DOI: 10.1186/s13072-018-0204-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
105 Kim W, Lee S, Son Y, Ko C, Ryu WS. DDB1 Stimulates Viral Transcription of Hepatitis B Virus via HBx-Independent Mechanisms. J Virol 2016;90:9644-53. [PMID: 27535046 DOI: 10.1128/JVI.00977-16] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
106 Gao Y, Zhang TY, Yuan Q, Xia NS. Antibody-mediated immunotherapy against chronic hepatitis B virus infection. Hum Vaccin Immunother 2017;13:1768-73. [PMID: 28521640 DOI: 10.1080/21645515.2017.1319021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
107 Caviglia GP, Abate ML, Tandoi F, Ciancio A, Amoroso A, Salizzoni M, Saracco GM, Rizzetto M, Romagnoli R, Smedile A. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection. J Hepatol. 2018;69:301-307. [PMID: 29621551 DOI: 10.1016/j.jhep.2018.03.021] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 14.5] [Reference Citation Analysis]
108 Pei Y, Wang C, Ben H, Wang L, Ma Y, Ma Q, Xiang Y, Zhang L, Liu G. Discovery of New Hepatitis B Virus Capsid Assembly Modulators by an Optimal High-Throughput Cell-Based Assay. ACS Infect Dis 2019;5:778-87. [PMID: 30761887 DOI: 10.1021/acsinfecdis.9b00030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
109 Lin G, Zhang K, Li J. Application of CRISPR/Cas9 Technology to HBV. Int J Mol Sci. 2015;16:26077-26086. [PMID: 26540039 DOI: 10.3390/ijms161125950] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
110 Wang H, Liu K, Fang BAM, Wu H, Li F, Xiang X, Tang W, Zhao G, Lin L, Bao S, Xie Q. Identification of acetyltransferase genes (HAT1 and KAT8) regulating HBV replication by RNAi screening. Cell Biosci 2015;5:66. [PMID: 26640654 DOI: 10.1186/s13578-015-0059-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
111 Kumar R, Pérez-Del-Pulgar S, Testoni B, Lebossé F, Zoulim F. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA. Liver Int 2016;36 Suppl 1:72-7. [PMID: 26725901 DOI: 10.1111/liv.13001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
112 Luo J, Luckenbaugh L, Hu H, Yan Z, Gao L, Hu J. Involvement of Host ATR-CHK1 Pathway in Hepatitis B Virus Covalently Closed Circular DNA Formation. mBio 2020;11:e03423-19. [PMID: 32071277 DOI: 10.1128/mBio.03423-19] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
113 Bao CY, Hung HC, Chen YW, Fan CY, Huang CJ, Huang W. Requirement of cyclin-dependent kinase function for hepatitis B virus cccDNA synthesis as measured by digital PCR. Ann Hepatol 2020;19:280-6. [PMID: 31964596 DOI: 10.1016/j.aohep.2019.12.005] [Reference Citation Analysis]
114 Hasegawa K, Nishikawa H, Enomoto H, Iwata Y, Sakai Y, Ikeda N, Takashima T, Aizawa N, Takata R, Yoh K, Ishii N, Yuri Y, Nishimura T, Iijima H, Hatano E, Fujimoto J, Nishiguchi S. Proposed model for the prediction of intrahepatic covalently closed circular DNA level in patients with chronic hepatitis B. Hepatol Res 2018;49:271-83. [DOI: 10.1111/hepr.13280] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
115 Hyrina A, Jones C, Chen D, Clarkson S, Cochran N, Feucht P, Hoffman G, Lindeman A, Russ C, Sigoillot F, Tsang T, Uehara K, Xie L, Ganem D, Holdorf M. A Genome-wide CRISPR Screen Identifies ZCCHC14 as a Host Factor Required for Hepatitis B Surface Antigen Production. Cell Rep 2019;29:2970-2978.e6. [PMID: 31801065 DOI: 10.1016/j.celrep.2019.10.113] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
116 Liu J, Wang T, Zhang W, Cheng Y, He Q, Wang FS. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int 2020;14:958-72. [PMID: 33185803 DOI: 10.1007/s12072-020-10099-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
117 Qi Y, Gao Z, Xu G, Peng B, Liu C, Yan H, Yao Q, Sun G, Liu Y, Tang D, Song Z, He W, Sun Y, Guo JT, Li W. DNA Polymerase κ Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus. PLoS Pathog 2016;12:e1005893. [PMID: 27783675 DOI: 10.1371/journal.ppat.1005893] [Cited by in Crossref: 88] [Cited by in F6Publishing: 92] [Article Influence: 14.7] [Reference Citation Analysis]
118 Lin N, Ye A, Lin J, Liu C, Huang J, Fu Y, Wu S, Xu S, Wang L, Ou Q. Diagnostic Value of Detection of Pregenomic RNA in Sera of Hepatitis B Virus-Infected Patients with Different Clinical Outcomes. J Clin Microbiol 2020;58:e01275-19. [PMID: 31723011 DOI: 10.1128/JCM.01275-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
119 Sugarman J, Revill P, Zoulim F, Yazdanpanah Y, Janssen HL, Lim SG, Lewin SR. Ethics and hepatitis B cure research. Gut 2017;66:389-92. [PMID: 27849559 DOI: 10.1136/gutjnl-2016-313009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
120 Liu Z, Wang J, Yuan H, Liu L, Bu Y, Zhao M, Yang G, Feng J, Liu Y, Li J, He Q, Zhang X. IFN-α2b inhibits the ethanol enriched-HBV cccDNA through blocking a positive feedback loop of HBx/MSL2/cccDNA/HBV/HBx in liver. Biochem Biophys Res Commun 2020;527:76-82. [PMID: 32446394 DOI: 10.1016/j.bbrc.2020.04.057] [Reference Citation Analysis]
121 Rybicka M, Bielawski KP. Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection. Microorganisms. 2020;8. [PMID: 32942584 DOI: 10.3390/microorganisms8091416] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
122 Dreyer T, Nicholson S, Ely A, Arbuthnot P, Bloom K. Improved antiviral efficacy using TALEN-mediated homology directed recombination to introduce artificial primary miRNAs into DNA of hepatitis B virus. Biochem Biophys Res Commun 2016;478:1563-8. [PMID: 27590580 DOI: 10.1016/j.bbrc.2016.08.152] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
123 Ivics Z, Amberger M, Zahn T, Hildt E. [Immunotherapies for the treatment of chronic hepatitis B virus infections-an overview with a focus on CAR T cells]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020;63:1357-64. [PMID: 32995895 DOI: 10.1007/s00103-020-03223-7] [Reference Citation Analysis]
124 Lang J, Neumann-haefelin C, Thimme R. Immunological cure of HBV infection. Hepatol Int 2019;13:113-24. [DOI: 10.1007/s12072-018-9912-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
125 Liu S, Zhang R. On an Age-Structured Hepatitis B Virus Infection Model with HBV DNA-Containing Capsids. Bull Malays Math Sci Soc 2021;44:1345-70. [DOI: 10.1007/s40840-020-01014-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
126 López-Gómez M, García de Santiago B, Delgado-López PD, Malmierca E, González-Olmedo J, Gómez-Raposo C, Sandoval C, Ruiz-Seco P, Escribano N, Gómez-Cerezo JF, Casado E. Gastrointestinal tumors and infectious agents: A wide field to explore. World J Meta-Anal 2021; 9(6): 505-521 [DOI: 10.13105/wjma.v9.i6.505] [Reference Citation Analysis]
127 Marchetti AL, Guo H. New Insights on Molecular Mechanism of Hepatitis B Virus Covalently Closed Circular DNA Formation. Cells 2020;9:E2430. [PMID: 33172220 DOI: 10.3390/cells9112430] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
128 Gherlan GS. Occult hepatitis B — the result of the host immune response interaction with different genomic expressions of the virus. World J Clin Cases 2022; 10(17): 5518-5530 [DOI: 10.12998/wjcc.v10.i17.5518] [Reference Citation Analysis]
129 Mu T, Zhao X, Zhu Y, Fan H, Tang H. The E3 Ubiquitin Ligase TRIM21 Promotes HBV DNA Polymerase Degradation. Viruses 2020;12:E346. [PMID: 32245233 DOI: 10.3390/v12030346] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
130 Meanwell NA. 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. J Med Chem 2016;59:7311-51. [PMID: 27501244 DOI: 10.1021/acs.jmedchem.6b00915] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
131 Umetsu T, Inoue J, Kogure T, Kakazu E, Ninomiya M, Iwata T, Takai S, Nakamura T, Sano A, Shimosegawa T. Inhibitory effect of silibinin on hepatitis B virus entry. Biochem Biophys Rep 2018;14:20-5. [PMID: 29872730 DOI: 10.1016/j.bbrep.2018.03.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
132 Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R, Zoulim F; Members of the ICE-HBV Working Groups., ICE-HBV Stakeholders Group Chairs., ICE-HBV Senior Advisors. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol 2019;4:545-58. [PMID: 30981686 DOI: 10.1016/S2468-1253(19)30119-0] [Cited by in Crossref: 210] [Cited by in F6Publishing: 142] [Article Influence: 70.0] [Reference Citation Analysis]
133 Faure-Dupuy S, Durantel D, Lucifora J. Liver macrophages: Friend or foe during hepatitis B infection? Liver Int 2018;38:1718-29. [PMID: 29772112 DOI: 10.1111/liv.13884] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
134 Feng J, Yang G, Liu Y, Gao Y, Zhao M, Bu Y, Yuan H, Yuan Y, Yun H, Sun M, Gao H, Zhang S, Liu Z, Yin M, Song X, Miao Z, Lin Z, Zhang X. LncRNA PCNAP1 modulates hepatitis B virus replication and enhances tumor growth of liver cancer. Theranostics 2019;9:5227-45. [PMID: 31410212 DOI: 10.7150/thno.34273] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 18.3] [Reference Citation Analysis]
135 Luo J, Cui X, Gao L, Hu J. Identification of an Intermediate in Hepatitis B Virus Covalently Closed Circular (CCC) DNA Formation and Sensitive and Selective CCC DNA Detection. J Virol. 2017;91. [PMID: 28637752 DOI: 10.1128/jvi.00539-17] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
136 Moyo B, Bloom K, Scott T, Ely A, Arbuthnot P. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus. Virus Res 2018;244:311-20. [PMID: 28087399 DOI: 10.1016/j.virusres.2017.01.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
137 Lai F, Wee CYY, Chen Q. Establishment of Humanized Mice for the Study of HBV. Front Immunol 2021;12:638447. [PMID: 33679796 DOI: 10.3389/fimmu.2021.638447] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
138 Ailioaie LM, Litscher G. Curcumin and Photobiomodulation in Chronic Viral Hepatitis and Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E7150. [PMID: 32998270 DOI: 10.3390/ijms21197150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
139 Wu CC, Chen YS, Cao L, Chen XW, Lu MJ. Hepatitis B virus infection: Defective surface antigen expression and pathogenesis. World J Gastroenterol 2018; 24(31): 3488-3499 [PMID: 30131655 DOI: 10.3748/wjg.v24.i31.3488] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
140 Verrier ER, Colpitts CC, Sureau C, Baumert TF. Hepatitis B virus receptors and molecular drug targets. Hepatol Int 2016;10:567-73. [DOI: 10.1007/s12072-016-9718-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
141 Tripodi G, Larsson SB, Norkrans G, Lindh M. Smaller reduction of hepatitis B virus DNA in liver tissue than in serum in patients losing HBeAg. J Med Virol. 2017;89:1937-1943. [PMID: 28464339 DOI: 10.1002/jmv.24841] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
142 Fourati S, Pawlotsky JM. Recent advances in understanding and diagnosing hepatitis B virus infection. F1000Res. 2016;5:pii: F1000. [PMID: 27635243 DOI: 10.12688/f1000research.8983.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
143 Sun Y, Teng Y, Wang L, Zhang Z, Chen C, Wang Y, Zhang X, Xiang P, Song X, Lu J, Li N, Gao L, Liang X, Xia Y, Wu Z, Ma C. LINC01431 Promotes Histone H4R3 Methylation to Impede HBV Covalently Closed Circular DNA Transcription by Stabilizing PRMT1. Adv Sci (Weinh) 2022;9:e2103135. [PMID: 35398991 DOI: 10.1002/advs.202103135] [Reference Citation Analysis]
144 Zhao F, Xie X, Tan X, Yu H, Tian M, Lv H, Qin C, Qi J, Zhu Q. The Functions of Hepatitis B Virus Encoding Proteins: Viral Persistence and Liver Pathogenesis. Front Immunol 2021;12:691766. [PMID: 34456908 DOI: 10.3389/fimmu.2021.691766] [Reference Citation Analysis]
145 Liu Y, Zeng W, Xi J, Liu H, Liao H, Yu G, Chen X, Lu F. Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: An updated occult HBV infection definition. Journal of Hepatology 2019;70:557-9. [DOI: 10.1016/j.jhep.2018.10.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
146 Ning Q, Wu D, Wang GQ, Ren H, Gao ZL, Hu P, Han MF, Wang Y, Zhang WH, Lu FM, Wang FS. Roadmap to functional cure of chronic hepatitis B: An expert consensus. J Viral Hepat 2019;26:1146-55. [PMID: 31087479 DOI: 10.1111/jvh.13126] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
147 Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. Journal of Hepatology 2016;64:S117-31. [DOI: 10.1016/j.jhep.2016.02.016] [Cited by in Crossref: 120] [Cited by in F6Publishing: 112] [Article Influence: 20.0] [Reference Citation Analysis]
148 Loglio A, Viganò M, Lampertico P. Novel Therapies That May Cure Chronic Hepatitis B Virus. Clin Liver Dis 2021;25:875-99. [PMID: 34593159 DOI: 10.1016/j.cld.2021.07.001] [Reference Citation Analysis]
149 Gajer M, Dörnbrack K, Rösler C, Schmid B, Beck J, Nassal M. Few basepairing-independent motifs in the apical half of the avian HBV ε RNA stem-loop determine site-specific initiation of protein-priming. Sci Rep 2017;7:7120. [PMID: 28769080 DOI: 10.1038/s41598-017-07657-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
150 Xie M, Yang Z, Liu Y, Zheng M. The role of HBV-induced autophagy in HBV replication and HBV related-HCC. Life Sciences 2018;205:107-12. [DOI: 10.1016/j.lfs.2018.04.051] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
151 Dezhbord M, Lee S, Kim W, Seong BL, Ryu WS. Characterization of the molecular events of covalently closed circular DNA synthesis in de novo Hepatitis B virus infection of human hepatoma cells. Antiviral Res 2019;163:11-8. [PMID: 30639437 DOI: 10.1016/j.antiviral.2019.01.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
152 Wang F, Zhou J, Li L, Wang M, Tao Y, Wang Y, Zhang D, Chen E. Serum Pregenomic RNA Combined With Hepatitis B Core-Related Antigen Helps Predict the Risk of Virological Relapse After Discontinuation of Nucleos(t)ide Analogs in Patients With Chronic Hepatitis B. Front Microbiol 2022;13:901233. [DOI: 10.3389/fmicb.2022.901233] [Reference Citation Analysis]
153 Ibrahim MK, Abdelhafez TH, Takeuchi JS, Wakae K, Sugiyama M, Tsuge M, Ito M, Watashi K, El Kassas M, Kato T, Murayama A, Suzuki T, Chayama K, Shimotohno K, Muramatsu M, Aly HH, Wakita T. MafF Is an Antiviral Host Factor That Suppresses Transcription from Hepatitis B Virus Core Promoter. J Virol 2021;95:e0076721. [PMID: 33980595 DOI: 10.1128/JVI.00767-21] [Reference Citation Analysis]
154 Chen L, Zhu C, Li F, Wang Y, Bao R, Cao Z, Xiang X, Yan L, Lin L, Zhao G, Xie Q, Bao S, Wang H. Correlation between hepatic human males absent on the first (hMOF) and viral persistence in chronic hepatitis B patients. Cell Biosci 2018;8:14. [PMID: 29484170 DOI: 10.1186/s13578-018-0215-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
155 Kitamura K, Que L, Shimadu M, Koura M, Ishihara Y, Wakae K, Nakamura T, Watashi K, Wakita T, Muramatsu M. Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus. PLoS Pathog. 2018;14:e1007124. [PMID: 29928064 DOI: 10.1371/journal.ppat.1007124] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 10.8] [Reference Citation Analysis]
156 Wu Z, Tan S, Xu L, Gao L, Zhu H, Ma C, Liang X. NgAgo-gDNA system efficiently suppresses hepatitis B virus replication through accelerating decay of pregenomic RNA. Antiviral Res 2017;145:20-3. [PMID: 28709658 DOI: 10.1016/j.antiviral.2017.07.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
157 Domingo E, Soria ME, Gallego I, de Ávila AI, García-Crespo C, Martínez-González B, Gómez J, Briones C, Gregori J, Quer J, Perales C. A new implication of quasispecies dynamics: Broad virus diversification in absence of external perturbations. Infect Genet Evol 2020;82:104278. [PMID: 32165244 DOI: 10.1016/j.meegid.2020.104278] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
158 Murata A, Angata K, Sogabe M, Sato S, Ichida T, Narimatsu H, Genda T. Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy. BMC Gastroenterol 2022;22:270. [PMID: 35641912 DOI: 10.1186/s12876-022-02352-4] [Reference Citation Analysis]
159 Chen C, Jia H, Zhang F, Qin Y, Zong L, Yuan Q, Wang Y, Xia N, Li J, Wen Y, Tong S. Functional characterization of hepatitis B virus core promoter mutants revealed transcriptional interference among co-terminal viral mRNAs. J Gen Virol 2016;97:2668-76. [PMID: 27558941 DOI: 10.1099/jgv.0.000590] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
160 Jiang C, Mei M, Li B, Zhu X, Zu W, Tian Y, Wang Q, Guo Y, Dong Y, Tan X. A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo. Cell Res 2017;27:440-3. [PMID: 28117345 DOI: 10.1038/cr.2017.16] [Cited by in Crossref: 145] [Cited by in F6Publishing: 140] [Article Influence: 29.0] [Reference Citation Analysis]
161 Nassal M. Chronic hepatitis B: divide and conquer? Gut 2018;67:400-2. [PMID: 28706078 DOI: 10.1136/gutjnl-2017-314255] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
162 Farag MS, van Campenhout MJH, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, van Vuuren AJ, Ferenci P, Feld JJ, Berg T, Hansen BE, van Bömmel F, Janssen HLA. Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B. Clin Infect Dis 2021;72:202-11. [PMID: 31912157 DOI: 10.1093/cid/ciaa013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
163 Ko C, Chakraborty A, Chou WM, Hasreiter J, Wettengel JM, Stadler D, Bester R, Asen T, Zhang K, Wisskirchen K, McKeating JA, Ryu WS, Protzer U. Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels. J Hepatol. 2018;69:1231-1241. [PMID: 30142426 DOI: 10.1016/j.jhep.2018.08.012] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 18.3] [Reference Citation Analysis]
164 Li F, Wang Z, Hu F, Su L. Cell Culture Models and Animal Models for HBV Study. Adv Exp Med Biol 2020;1179:109-35. [PMID: 31741335 DOI: 10.1007/978-981-13-9151-4_5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
165 Xi J, Luckenbaugh L, Hu J. Multiple roles of PP2A binding motif in hepatitis B virus core linker and PP2A in regulating core phosphorylation state and viral replication. PLoS Pathog 2021;17:e1009230. [PMID: 33493210 DOI: 10.1371/journal.ppat.1009230] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
166 Takata A, Otsuka M, Ohno M, Kishikawa T, Yoshikawa T, Koike K. Mutual antagonism between hepatitis B viral mRNA and host microRNA let-7. Sci Rep. 2016;6:23237. [PMID: 26979389 DOI: 10.1038/srep23237] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
167 Boyd A, Lacombe K, Lavocat F, Maylin S, Miailhes P, Lascoux-Combe C, Delaugerre C, Girard PM, Zoulim F. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. J Hepatol. 2016;65:683-691. [PMID: 27210429 DOI: 10.1016/j.jhep.2016.05.014] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 10.3] [Reference Citation Analysis]
168 Virzì A, Gonzalez-Motos V, Tripon S, Baumert TF, Lupberger J. Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development. J Clin Med 2021;10:977. [PMID: 33801181 DOI: 10.3390/jcm10050977] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
169 Shih C, Wu SY, Chou SF, Yuan TT. Virion Secretion of Hepatitis B Virus Naturally Occurring Core Antigen Variants. Cells 2020;10:E43. [PMID: 33396864 DOI: 10.3390/cells10010043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
170 Teng Y, Xu Z, Zhao K, Zhong Y, Wang J, Zhao L, Zheng Z, Hou W, Zhu C, Chen X, Protzer U, Li Y, Xia Y. Novel function of SART1 in HNF4α transcriptional regulation contributes to its antiviral role during HBV infection. J Hepatol 2021:S0168-8278(21)01888-2. [PMID: 34242702 DOI: 10.1016/j.jhep.2021.06.038] [Reference Citation Analysis]
171 Block TM, Guo J. The Covalently Closed Circular Form of Hepatitis B Virus Genome: Is There Now an End in “Site”? Gastroenterology 2016;150:34-6. [DOI: 10.1053/j.gastro.2015.11.032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
172 Huang H, Wang J, Li W, Chen R, Chen X, Zhang F, Xu D, Lu F. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals. J Clin Virol 2018;99-100:71-8. [PMID: 29353073 DOI: 10.1016/j.jcv.2017.12.016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
173 Slagle BL, Bouchard MJ. Role of HBx in hepatitis B virus persistence and its therapeutic implications. Curr Opin Virol 2018;30:32-8. [PMID: 29454995 DOI: 10.1016/j.coviro.2018.01.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
174 Liu Y, Feng J, Sun M, Yang G, Yuan H, Wang Y, Bu Y, Zhao M, Zhang S, Zhang X. Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma. Cancer Lett. 2019;454:158-170. [PMID: 30981758 DOI: 10.1016/j.canlet.2019.04.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 9.7] [Reference Citation Analysis]
175 Nakamura T, Inoue J, Ninomiya M, Kakazu E, Iwata T, Takai S, Sano A, Kogure T, Shimosegawa T, Masamune A. Effect of viral DNA methylation on expression of hepatitis B virus proteins depends on the virus genotype. Virus Genes 2020;56:439-47. [PMID: 32361814 DOI: 10.1007/s11262-020-01761-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
176 Dishlers A, Skrastina D, Renhofa R, Petrovskis I, Ose V, Lieknina I, Jansons J, Pumpens P, Sominskaya I. The Hepatitis B Virus Core Variants that Expose Foreign C-Terminal Insertions on the Outer Surface of Virus-Like Particles. Mol Biotechnol 2015;57:1038-49. [PMID: 26446016 DOI: 10.1007/s12033-015-9895-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
177 Tu T, Budzinska MA, Vondran FWR, Shackel NA, Urban S. Hepatitis B Virus DNA Integration Occurs Early in the Viral Life Cycle in an In Vitro Infection Model via Sodium Taurocholate Cotransporting Polypeptide-Dependent Uptake of Enveloped Virus Particles. J Virol 2018;92:e02007-17. [PMID: 29437961 DOI: 10.1128/JVI.02007-17] [Cited by in Crossref: 63] [Cited by in F6Publishing: 41] [Article Influence: 15.8] [Reference Citation Analysis]
178 Zhang S, Sang X, Hou D, Chen J, Gu H, Zhang Y, Li J, Yang D, Zhu H, Yang X, Wang F, Zhang C, Chen X, Zen K, Zhang C, Hong Z. Plant-derived RNAi therapeutics: A strategic inhibitor of HBsAg. Biomaterials 2019;210:83-93. [DOI: 10.1016/j.biomaterials.2019.04.033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
179 Nosaka T, Naito T, Murata Y, Matsuda H, Ohtani M, Hiramatsu K, Nishizawa T, Okamoto H, Nakamoto Y. Regulatory function of interferon-inducible 44-like for hepatitis B virus covalently closed circular DNA in primary human hepatocytes. Hepatol Res 2021. [PMID: 34697871 DOI: 10.1111/hepr.13722] [Reference Citation Analysis]
180 Wu SY, Lan SH, Liu HS. Autophagy and microRNA in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 176-187 [PMID: 26755869 DOI: 10.3748/wjg.v22.i1.176] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
181 Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yang Z. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver. 2019;. [PMID: 31158948 DOI: 10.5009/gnl18546.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
182 Schinazi RF, Ehteshami M, Bassit L, Asselah T. Towards HBV curative therapies. Liver Int 2018;38 Suppl 1:102-14. [PMID: 29427479 DOI: 10.1111/liv.13656] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 12.7] [Reference Citation Analysis]
183 Balagopal A, Grudda T, Ribeiro RM, Saad YS, Hwang HS, Quinn J, Murphy M, Ward K, Sterling RK, Zhang Y, Perelson AS, Sulkowski MS, Osburn WO, Thio CL. Single hepatocytes show persistence and transcriptional inactivity of hepatitis B. JCI Insight 2020;5:140584. [PMID: 33004689 DOI: 10.1172/jci.insight.140584] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
184 Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18:827-844. [PMID: 31455905 DOI: 10.1038/s41573-019-0037-0] [Cited by in Crossref: 118] [Cited by in F6Publishing: 130] [Article Influence: 39.3] [Reference Citation Analysis]
185 Rat V, Pinson X, Seigneuret F, Durand S, Herrscher C, Lemoine R, Burlaud-Gaillard J, Raynal PY, Hourioux C, Roingeard P, Tramier M, de Rocquigny H. Hepatitis B Virus Core Protein Domains Essential for Viral Capsid Assembly in a Cellular Context. J Mol Biol 2020;432:3802-19. [PMID: 32371046 DOI: 10.1016/j.jmb.2020.04.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
186 Li X, Xu Z, Mitra B, Wang M, Guo H, Feng Z. Elevated NTCP expression by an iPSC-derived human hepatocyte maintenance medium enhances HBV infection in NTCP-reconstituted HepG2 cells. Cell Biosci 2021;11:123. [PMID: 34225786 DOI: 10.1186/s13578-021-00641-1] [Reference Citation Analysis]
187 Wan H, Ge L, Xiao L, Li J, Wu W, Peng S, Huang J, Zhou B, Zeng X. 3,4,5-Tri-O-caffeoylquinic acid methyl ester isolated from Lonicera japonica Thunb. Flower buds facilitates hepatitis B virus replication in HepG2.2.15 cells. Food Chem Toxicol 2020;138:111250. [PMID: 32156566 DOI: 10.1016/j.fct.2020.111250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
188 Chiale C, Moshkani S, Rose JK, Robek MD. Heterologous prime-boost immunization with vesiculovirus-based vectors expressing HBV Core antigen induces CD8+ T cell responses in naïve and persistently infected mice and protects from challenge. Antiviral Res 2019;168:156-67. [PMID: 31153968 DOI: 10.1016/j.antiviral.2019.05.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
189 Wang Z. Challenges and Opportunities in Hepatitis B Research. ACS Infect Dis 2019;5:652-4. [PMID: 31072103 DOI: 10.1021/acsinfecdis.9b00136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
190 Que L, Liu G, Kitamura K, Wakae K, Li Y, Nishitsuji H, Ujino S, Shimotohno K, Muramatsu M. Molecular characterization of AID-mediated reduction of hepatitis B virus transcripts. Virology 2017;510:281-8. [PMID: 28779685 DOI: 10.1016/j.virol.2017.07.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
191 Yang H, Zhou Y, Mo J, Xiang Q, Qin M, Liu W, Shang J, Yang Q, Xu W, Yang G, Tan Q, Wu K, Liu Y, Wu J. SOX9 represses hepatitis B virus replication through binding to HBV EnhII/Cp and inhibiting the promoter activity. Antiviral Res 2020;177:104761. [PMID: 32147495 DOI: 10.1016/j.antiviral.2020.104761] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
192 Luo J, Xi J, Gao L, Hu J. Role of Hepatitis B virus capsid phosphorylation in nucleocapsid disassembly and covalently closed circular DNA formation. PLoS Pathog 2020;16:e1008459. [PMID: 32226051 DOI: 10.1371/journal.ppat.1008459] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
193 Tan G, Yi Z, Song H, Xu F, Li F, Aliyari R, Zhang H, Du P, Ding Y, Niu J, Wang X, Su L, Qin FX, Cheng G. Type-I-IFN-Stimulated Gene TRIM5γ Inhibits HBV Replication by Promoting HBx Degradation. Cell Rep 2019;29:3551-3563.e3. [PMID: 31825835 DOI: 10.1016/j.celrep.2019.11.041] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
194 Ringelhan M, Protzer U. Oncogenic potential of hepatitis B virus encoded proteins. Curr Opin Virol 2015;14:109-15. [PMID: 26426688 DOI: 10.1016/j.coviro.2015.08.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
195 Campos-Valdez M, Monroy-Ramírez HC, Armendáriz-Borunda J, Sánchez-Orozco LV. Molecular Mechanisms during Hepatitis B Infection and the Effects of the Virus Variability. Viruses 2021;13:1167. [PMID: 34207116 DOI: 10.3390/v13061167] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Priyambada SA, Misaki R, Okamoto T, Ohashi T, Ueda K, Matsuura Y, Fujiyama K. St6gal1 knockdown alters HBV life cycle in HepAD38 cells. Biochem Biophys Res Commun 2018;503:1841-7. [PMID: 30057317 DOI: 10.1016/j.bbrc.2018.07.124] [Reference Citation Analysis]
197 Beloukas A, Geretti AM. Hepatitis B Virus Drug Resistance. In: Mayers DL, Sobel JD, Ouellette M, Kaye KS, Marchaim D, editors. Antimicrobial Drug Resistance. Cham: Springer International Publishing; 2017. pp. 1227-42. [DOI: 10.1007/978-3-319-47266-9_26] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
198 Allweiss L, Dandri M. Experimental in vitro and in vivo models for the study of human hepatitis B virus infection. J Hepatol. 2016;64:S17-S31. [PMID: 27084033 DOI: 10.1016/j.jhep.2016.02.012] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 14.4] [Reference Citation Analysis]
199 Huang M, Liu J, Chow M, Zhou X, Han Z, He Z, Xue J, Zhu Z, Li X, Xia J. Negative HBcAg in immunohistochemistry assay of liver biopsy is a predictive factor for the treatment of patients with nucleos(t)ide analogue therapy. J Cell Mol Med 2018;22:1675-83. [PMID: 29193766 DOI: 10.1111/jcmm.13444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
200 Wei L, Ploss A. Hepatitis B virus cccDNA is formed through distinct repair processes of each strand. Nat Commun 2021;12:1591. [PMID: 33707452 DOI: 10.1038/s41467-021-21850-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
201 Chen G, Wang C, Lau G. Treatment of chronic hepatitis B infection-2017. Liver Int 2017;37:59-66. [DOI: 10.1111/liv.13309] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
202 Li J, Wu Z, Wang GQ, Zhao H. Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients. Chin Med J (Engl) 2021;134:1160-7. [PMID: 33734135 DOI: 10.1097/CM9.0000000000001418] [Reference Citation Analysis]
203 Beck J, Seitz S, Lauber C, Nassal M. Conservation of the HBV RNA element epsilon in nackednaviruses reveals ancient origin of protein-primed reverse transcription. Proc Natl Acad Sci U S A 2021;118:e2022373118. [PMID: 33753499 DOI: 10.1073/pnas.2022373118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Tang L, Sheraz M, McGrane M, Chang J, Guo JT. DNA Polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA. PLoS Pathog. 2019;15:e1007742. [PMID: 31026293 DOI: 10.1371/journal.ppat.1007742] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
205 Chulanov VP, Zueva AP, Kostyushev DS, Brezgin SA, Volchkova EV, Maleyev VV. [Hepatitis C can be cured: will hepatitis B become next?]. Ter Arkh 2017;89:4-13. [PMID: 29260740 DOI: 10.17116/terarkh201789114-13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
206 Uchida T, Imamura M, Hayes CN, Hiraga N, Kan H, Tsuge M, Abe-Chayama H, Zhang Y, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice. Antimicrob Agents Chemother 2017;61:e00725-17. [PMID: 28696237 DOI: 10.1128/AAC.00725-17] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
207 Allweiss L, Dandri M. The Role of cccDNA in HBV Maintenance. Viruses. 2017;9:156. [PMID: 28635668 DOI: 10.3390/v9060156] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 12.6] [Reference Citation Analysis]
208 Martinez MG, Villeret F, Testoni B, Zoulim F. Can we cure hepatitis B virus with novel direct-acting antivirals? Liver Int 2020;40 Suppl 1:27-34. [PMID: 32077597 DOI: 10.1111/liv.14364] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 21.0] [Reference Citation Analysis]
209 Asselah T, Loureiro D, Boyer N, Mansouri A. Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure. The Lancet Gastroenterology & Hepatology 2019;4:883-92. [DOI: 10.1016/s2468-1253(19)30190-6] [Cited by in Crossref: 47] [Cited by in F6Publishing: 23] [Article Influence: 15.7] [Reference Citation Analysis]
210 Osiowy C, Coffin C, Andonov A. Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy. Curr Treat Options Infect Dis 2016;8:177-93. [PMID: 27547127 DOI: 10.1007/s40506-016-0080-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
211 Peng C, Lu M, Yang D. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV. Virol Sin. 2015;30:317-325. [PMID: 26511989 DOI: 10.1007/s12250-015-3660-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
212 Ingasia LAO, Kostaki EG, Paraskevis D, Kramvis A. Global and regional dispersal patterns of hepatitis B virus genotype E from and in Africa: A full-genome molecular analysis. PLoS One 2020;15:e0240375. [PMID: 33031453 DOI: 10.1371/journal.pone.0240375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
213 Yang YC, Yang HC. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas. Viruses 2021;14:4. [PMID: 35062208 DOI: 10.3390/v14010004] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
214 Liu S, Zhou B, Valdes JD, Sun J, Guo H. Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection. Hepatology 2019;69:1816-27. [PMID: 30362148 DOI: 10.1002/hep.30325] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 28.7] [Reference Citation Analysis]
215 Emery JS, Feld JJ. Treatment of hepatitis B virus with combination therapy now and in the future. Best Pract Res Clin Gastroenterol. 2017;31:347-355. [PMID: 28774417 DOI: 10.1016/j.bpg.2017.04.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
216 Liu Y, Liu H, Hu Z, Ding Y, Pan XB, Zou J, Xi J, Yu G, Huang H, Luo MT, Guo F, Liu S, Sheng Q, Jia J, Zheng YT, Wang J, Chen X, Guo JT, Wei L, Lu F. Hepatitis B Virus Virions Produced Under Nucleos(t)ide Analogue Treatment Are Mainly Not Infectious Because of Irreversible DNA Chain Termination. Hepatology 2020;71:463-76. [PMID: 31278760 DOI: 10.1002/hep.30844] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
217 Zhao K, Liu A, Xia Y. Insights into Hepatitis B Virus DNA Integration-55 Years after Virus Discovery. The Innovation 2020;1:100034. [DOI: 10.1016/j.xinn.2020.100034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
218 Kostyushev DS, Zueva AP, Brezgin SA, Lipatnikov AD, Simirskii VN, Glebe D, Volchkova EV, Shipulin GA, Chulanov VP. [Overexpression of DNA-methyltransferases in persistency of cccDNA pool in chronic hepatitis B]. Ter Arkh 2017;89:21-6. [PMID: 29260742 DOI: 10.17116/terarkh2017891121-26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
219 Liu J, Li T, Zhang L, Xu A. The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review. Hepatology 2019;70:1045-55. [PMID: 30561829 DOI: 10.1002/hep.30474] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 21.0] [Reference Citation Analysis]
220 Li X, Liu H, Cheng W, Wang J, Zhang H, Lu F, Chen X, Lin W. Junceellolide B, a novel inhibitor of Hepatitis B virus. Bioorg Med Chem 2020;28:115603. [PMID: 32690259 DOI: 10.1016/j.bmc.2020.115603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
221 Zheng J, Lin X, Wang X, Zheng L, Lan S, Jin S, Ou Z, Wu J. In Silico Analysis of Epitope-Based Vaccine Candidates against Hepatitis B Virus Polymerase Protein. Viruses 2017;9:E112. [PMID: 28509875 DOI: 10.3390/v9050112] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
222 Zhang B, Liu Y, Wang X, Li J, Xu X, Guo L, Ho WZ. TLR3 Activation of Hepatic Stellate Cell Line Suppresses HBV Replication in HepG2 Cells. Front Immunol 2018;9:2921. [PMID: 30619284 DOI: 10.3389/fimmu.2018.02921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
223 Broennimann K, Ricardo-lax I, Adler J, Shaul Y. Evidence for a Hepatitis B Virus Short RNA Fragment Directly Targeting the Cellular RRM2 Gene. Cells 2022;11:2248. [DOI: 10.3390/cells11142248] [Reference Citation Analysis]
224 Mnyandu N, Limani SW, Arbuthnot P, Maepa MB. Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics. Virol J 2021;18:247. [PMID: 34903258 DOI: 10.1186/s12985-021-01715-9] [Reference Citation Analysis]
225 Mutz P, Metz P, Lempp FA, Bender S, Qu B, Schöneweis K, Seitz S, Tu T, Restuccia A, Frankish J, Dächert C, Schusser B, Koschny R, Polychronidis G, Schemmer P, Hoffmann K, Baumert TF, Binder M, Urban S, Bartenschlager R. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon. Gastroenterology 2018;154:1791-1804.e22. [PMID: 29410097 DOI: 10.1053/j.gastro.2018.01.044] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 18.8] [Reference Citation Analysis]
226 Li Y, Xia Y, Han M, Chen G, Zhang D, Thasler WE, Protzer U, Ning Q. IFN-α-mediated Base Excision Repair Pathway Correlates with Antiviral Response Against Hepatitis B Virus Infection. Sci Rep 2017;7:12715. [PMID: 28983111 DOI: 10.1038/s41598-017-13082-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
227 Hu J, Liu K. Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application. Viruses. 2017;9. [PMID: 28335554 DOI: 10.3390/v9030056] [Cited by in Crossref: 120] [Cited by in F6Publishing: 110] [Article Influence: 24.0] [Reference Citation Analysis]
228 Xia Y, Guo H. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential. Antiviral Res. 2020;180:104824. [PMID: 32450266 DOI: 10.1016/j.antiviral.2020.104824] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 9.5] [Reference Citation Analysis]
229 Dong J, Ying J, Qiu X, Lu Y, Zhang M. Advanced Strategies for Eliminating the cccDNA of HBV. Dig Dis Sci 2018;63:7-15. [PMID: 29159681 DOI: 10.1007/s10620-017-4842-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
230 Zhang W, Chen J, Wu M, Zhang X, Zhang M, Yue L, Li Y, Liu J, Li B, Shen F, Wang Y, Bai L, Protzer U, Levrero M, Yuan Z. PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation. Hepatology 2017;66:398-415. [PMID: 28236308 DOI: 10.1002/hep.29133] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 14.2] [Reference Citation Analysis]
231 Yang MH, Chen M, Mo HH, Tsai WC, Chang YC, Chang CC, Chen KC, Wu HY, Yuan CH, Lee CH, Chen YA, Tyan YC. Utilizing Experimental Mouse Model to Identify Effectors of Hepatocellular Carcinoma Induced by HBx Antigen. Cancers (Basel) 2020;12:E409. [PMID: 32050622 DOI: 10.3390/cancers12020409] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
232 Long Q, Yan R, Hu J, Cai D, Mitra B, Kim ES, Marchetti A, Zhang H, Wang S, Liu Y, Huang A, Guo H. The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation. PLoS Pathog 2017;13:e1006784. [PMID: 29287110 DOI: 10.1371/journal.ppat.1006784] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 10.8] [Reference Citation Analysis]
233 Li B, Sun S, Li M, Cheng X, Li H, Kang F, Kang J, Dörnbrack K, Nassal M, Sun D. Suppression of hepatitis B virus antigen production and replication by wild-type HBV dependently replicating HBV shRNA vectors in vitro and in vivo. Antiviral Res 2016;134:117-29. [PMID: 27591142 DOI: 10.1016/j.antiviral.2016.08.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
234 Novotny LA, Evans JG, Su L, Guo H, Meissner EG. Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies. Viruses 2021;13:1090. [PMID: 34207487 DOI: 10.3390/v13061090] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
235 Pan J, Tong S, Kang L, Tang J. New anti-hepatitis B virus drugs under development and evaluation: . Current Opinion in Infectious Diseases 2016;29:632-8. [DOI: 10.1097/qco.0000000000000318] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
236 Liu L, Yang J, Men K, He Z, Luo M, Qian Z, Wei X, Wei Y. Current Status of Nonviral Vectors for Gene Therapy in China. Human Gene Therapy 2018;29:110-20. [DOI: 10.1089/hum.2017.226] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
237 Liu T, Sun Q, Liu Y, Cen S, Zhang Q. The MOV10 helicase restricts hepatitis B virus replication by inhibiting viral reverse transcription. J Biol Chem 2019;294:19804-13. [PMID: 31722967 DOI: 10.1074/jbc.RA119.009435] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
238 Lin J, Li J, Xie P, Han Y, Yu D, Chen J, Zhang X. Hepatitis B virus middle surface antigen loss promotes clinical variant persistence in mouse models. Virulence 2021;12:2868-82. [PMID: 34738866 DOI: 10.1080/21505594.2021.1999130] [Reference Citation Analysis]
239 Ringelhan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci. 2017;372. [PMID: 28893941 DOI: 10.1098/rstb.2016.0274] [Cited by in Crossref: 100] [Cited by in F6Publishing: 94] [Article Influence: 25.0] [Reference Citation Analysis]
240 Lomonosova E, Tavis JE. In Vitro Enzymatic and Cell Culture-Based Assays for Measuring Activity of HBV RNaseH Inhibitors. Methods Mol Biol 2017;1540:179-92. [PMID: 27975316 DOI: 10.1007/978-1-4939-6700-1_14] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
241 Alonso S, Guerra AR, Carreira L, Ferrer JÁ, Gutiérrez ML, Fernandez-Rodriguez CM. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon? BMC Gastroenterol 2017;17:168. [PMID: 29268704 DOI: 10.1186/s12876-017-0726-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
242 Li X, Zhao J, Yuan Q, Xia N. Detection of HBV Covalently Closed Circular DNA. Viruses 2017;9:E139. [PMID: 28587292 DOI: 10.3390/v9060139] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
243 Jacobs R, Singh P, Smith T, Arbuthnot P, Maepa MB. Prospects of viral vector-mediated delivery of sequences encoding anti-HBV designer endonucleases. Gene Ther 2022. [PMID: 35606493 DOI: 10.1038/s41434-022-00342-5] [Reference Citation Analysis]
244 Verrier ER, Colpitts CC, Schuster C, Zeisel MB, Baumert TF. Cell Culture Models for the Investigation of Hepatitis B and D Virus Infection. Viruses 2016;8:E261. [PMID: 27657111 DOI: 10.3390/v8090261] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
245 Xu R, Hu P, Li Y, Tian A, Li J, Zhu C. Advances in HBV infection and replication systems in vitro. Virol J 2021;18:105. [PMID: 34051803 DOI: 10.1186/s12985-021-01580-6] [Reference Citation Analysis]
246 Tang D, Zhao H, Wu Y, Peng B, Gao Z, Sun Y, Duan J, Qi Y, Li Y, Zhou Z, Guo G, Zhang Y, Li C, Sui J, Li W. Transcriptionally inactive hepatitis B virus episome DNA preferentially resides in the vicinity of chromosome 19 in 3D host genome upon infection. Cell Rep 2021;35:109288. [PMID: 34192543 DOI: 10.1016/j.celrep.2021.109288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
247 Huang D, Wu D, Wang P, Wang Y, Yuan W, Hu D, Hu J, Wang Y, Tao R, Xiao F, Zhang X, Wang X, Han M, Luo X, Yan W, Ning Q. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol 2022:S0168-8278(22)00066-6. [PMID: 35149125 DOI: 10.1016/j.jhep.2022.01.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
248 Murphy CM, Xu Y, Li F, Nio K, Reszka-Blanco N, Li X, Wu Y, Yu Y, Xiong Y, Su L. Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication. Cell Rep. 2016;16:2846-2854. [PMID: 27626656 DOI: 10.1016/j.celrep.2016.08.026] [Cited by in Crossref: 114] [Cited by in F6Publishing: 114] [Article Influence: 22.8] [Reference Citation Analysis]
249 Durantel D, Kusters I, Louis J, Manel N, Ottenhoff THM, Picot V, Saaadatian-Elahi M. Mechanisms behind TB, HBV, and HIV chronic infections. Infect Genet Evol 2017;55:142-50. [PMID: 28919545 DOI: 10.1016/j.meegid.2017.09.008] [Reference Citation Analysis]
250 Liu S, Jia R, Li Q, Feng D, Shen H, Yang C, Wang M, Zhu D, Chen S, Liu M, Zhao X, Yin Z, Jing B, Cheng A. Immunogenicity and protective efficacy of DHBV DNA vaccines expressing envelope and capsid fusion proteins in ducks delivered by attenuated Salmonella typhimurium. Journal of Integrative Agriculture 2018;17:928-39. [DOI: 10.1016/s2095-3119(17)61829-x] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
251 Lang-Meli J, Neumann-Haefelin C, Thimme R. Immunotherapy and therapeutic vaccines for chronic HBV infection. Curr Opin Virol 2021;51:149-57. [PMID: 34710645 DOI: 10.1016/j.coviro.2021.10.002] [Reference Citation Analysis]
252 Yang H, Chen P. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA. Virus Research 2018;244:304-10. [DOI: 10.1016/j.virusres.2017.06.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
253 Balagopal A, Hwang HS, Grudda T, Quinn J, Sterling RK, Sulkowski MS, Thio CL. Single Hepatocyte Hepatitis B Virus Transcriptional Landscape in HIV Coinfection. J Infect Dis. 2020;221:1462-1469. [PMID: 31740931 DOI: 10.1093/infdis/jiz607] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
254 Farrokhzadeh A, Badichi Akher F, Olotu FA, Van Heerden FR. Impact of HEC72702 chirality on the selective inhibition of hepatitis B virus capsid dimer: A dynamics-structure-energetics perspective. Chem Biol Drug Des 2021;97:167-83. [PMID: 32757484 DOI: 10.1111/cbdd.13771] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
255 Zhang TY, Guo XR, Wu YT, Kang XZ, Zheng QB, Qi RY, Chen BB, Lan Y, Wei M, Wang SJ, Xiong HL, Cao JL, Zhang BH, Qiao XY, Huang XF, Wang YB, Fang MJ, Zhang YL, Cheng T, Chen YX, Zhao QJ, Li SW, Ge SX, Chen PJ, Zhang J, Yuan Q, Xia NS. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut 2020;69:343-54. [PMID: 30926653 DOI: 10.1136/gutjnl-2018-317725] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
256 Wang Z, Chen Y, Deng H, Zhen X, Xiong J, Hu Y. Quantification of intrahepatic cccDNA in HBV associated hepatocellular carcinoma by improved ddPCR method. J Virol Methods 2022;299:114334. [PMID: 34688781 DOI: 10.1016/j.jviromet.2021.114334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
257 Lucifora J, Protzer U. Attacking hepatitis B virus cccDNA--The holy grail to hepatitis B cure. J Hepatol. 2016;64:S41-S48. [PMID: 27084036 DOI: 10.1016/j.jhep.2016.02.009] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 19.0] [Reference Citation Analysis]
258 Guo L, Gao S, Sun W, Wang Y, Zhao J. Elevated LINC01232 is associated with poor prognosis and HBV infection in hepatocellular carcinoma patients and contributes to tumor progression in vitro. Clin Res Hepatol Gastroenterol 2021;:101813. [PMID: 34583064 DOI: 10.1016/j.clinre.2021.101813] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
259 Stella L, Santopaolo F, Gasbarrini A, Pompili M, Ponziani FR. Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment. World J Gastroenterol 2022; 28(21): 2251-2281 [DOI: 10.3748/wjg.v28.i21.2251] [Reference Citation Analysis]
260 D'souza S, Lau KCK, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol 2020; 26(38): 5759-5783 [PMID: 33132633 DOI: 10.3748/wjg.v26.i38.5759] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 42] [Article Influence: 24.5] [Reference Citation Analysis]
261 Zhang Z, Zehnder B, Damrau C, Urban S. Visualization of hepatitis B virus entry - novel tools and approaches to directly follow virus entry into hepatocytes. FEBS Lett 2016;590:1915-26. [PMID: 27149321 DOI: 10.1002/1873-3468.12202] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
262 Levrero M, Subic M, Villeret F, Zoulim F. Perspectives and limitations for nucleo(t)side analogs in future HBV therapies. Current Opinion in Virology 2018;30:80-9. [DOI: 10.1016/j.coviro.2018.04.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
263 Wang L, Cao X, Wang Z, Gao Y, Deng J, Liu X, Zhuang H. Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients. J Clin Microbiol 2019;57:e01303-18. [PMID: 30355757 DOI: 10.1128/JCM.01303-18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
264 Yu K, Li Q, Cheng Q, Huang C, Zheng J, Chen S, Ling Q, Zhu M, Chen M, Shi G, Li N. MicroRNA-548j inhibits type I interferon production by targeting ZBTB11 in patients with chronic hepatitis B. Biochemical and Biophysical Research Communications 2017;488:628-33. [DOI: 10.1016/j.bbrc.2017.03.109] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
265 Niklasch M, Zimmermann P, Nassal M. The Hepatitis B Virus Nucleocapsid-Dynamic Compartment for Infectious Virus Production and New Antiviral Target. Biomedicines 2021;9:1577. [PMID: 34829806 DOI: 10.3390/biomedicines9111577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Kankanala J, Marchand C, Abdelmalak M, Aihara H, Pommier Y, Wang Z. Isoquinoline-1,3-diones as Selective Inhibitors of Tyrosyl DNA Phosphodiesterase II (TDP2). J Med Chem 2016;59:2734-46. [PMID: 26910725 DOI: 10.1021/acs.jmedchem.5b01973] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
267 McNaughton AL, D'Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, McKeating JA, Matthews PC. Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood. Gastroenterology 2019;156:384-99. [PMID: 30268787 DOI: 10.1053/j.gastro.2018.07.058] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 11.0] [Reference Citation Analysis]
268 Yamamoto Y, Kakizaki M, Shimizu T, Carreras J, Chiba T, Chamoto K, Kagawa T, Aoki T, Nakamura N, Ando K, Kotani A. PD-L1 is induced on the hepatocyte surface via CKLF-like MARVEL transmembrane domain-containing protein 6 up-regulation by the anti-HBV drug Entecavir. Int Immunol 2020;32:519-31. [PMID: 32219331 DOI: 10.1093/intimm/dxaa018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
269 Cui D, Li W, Jiang D, Wu J, Xie J, Wu Y. Advances in Multi-Omics Applications in HBV-Associated Hepatocellular Carcinoma. Front Med (Lausanne) 2021;8:754709. [PMID: 34660653 DOI: 10.3389/fmed.2021.754709] [Reference Citation Analysis]
270 Moon IY, Kim JW. Methylation profile of hepatitis B virus is not influenced by interferon α in human liver cancer cells. Mol Med Rep 2021;24:715. [PMID: 34396432 DOI: 10.3892/mmr.2021.12354] [Reference Citation Analysis]
271 Gu C, Tao S, Hu K, Ming L, Luo M, Guo H, Su Y, Liu J, Xie Y. Establishment of an in vitro reporter system for screening HBx-targeting molecules. Acta Biochim Biophys Sin (Shanghai) 2019;51:431-40. [PMID: 30811522 DOI: 10.1093/abbs/gmz016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
272 Huang JT, Yang Y, Hu YM, Liu XH, Liao MY, Morgan R, Yuan EF, Li X, Liu SM. A Highly Sensitive and Robust Method for Hepatitis B Virus Covalently Closed Circular DNA Detection in Single Cells and Serum. J Mol Diagn. 2018;20:334-343. [PMID: 29656833 DOI: 10.1016/j.jmoldx.2018.01.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
273 Bertoletti A, Tan AT. HBV as a target for CAR or TCR-T cell therapy. Curr Opin Immunol 2020;66:35-41. [PMID: 32361634 DOI: 10.1016/j.coi.2020.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
274 Deng JJ, Kong KE, Gao WW, Tang HV, Chaudhary V, Cheng Y, Zhou J, Chan CP, Wong DK, Yuen MF, Jin DY. Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription. Biochim Biophys Acta Gene Regul Mech. 2017;1860:491-501. [PMID: 28242208 DOI: 10.1016/j.bbagrm.2017.02.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
275 Eller C, Heydmann L, Colpitts CC, El Saghire H, Piccioni F, Jühling F, Majzoub K, Pons C, Bach C, Lucifora J, Lupberger J, Nassal M, Cowley GS, Fujiwara N, Hsieh SY, Hoshida Y, Felli E, Pessaux P, Sureau C, Schuster C, Root DE, Verrier ER, Baumert TF. A genome-wide gain-of-function screen identifies CDKN2C as a HBV host factor. Nat Commun 2020;11:2707. [PMID: 32483149 DOI: 10.1038/s41467-020-16517-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
276 Briday M, Hallé F, Lecoq L, Radix S, Martin J, Montserret R, Dujardin M, Fogeron M, Nassal M, Meier BH, Lomberget T, Böckmann A. Pharmacomodulation of a ligand targeting the HBV capsid hydrophobic pocket. Chem Sci . [DOI: 10.1039/d2sc02420a] [Reference Citation Analysis]
277 Zhang X, Yue L, Zhang Z, Yuan Z. Establishment of a fluorescent in situ hybridization assay for imaging hepatitis B virus nucleic acids in cell culture models. Emerg Microbes Infect 2017;6:e98. [PMID: 29116221 DOI: 10.1038/emi.2017.84] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
278 Li J, Sun X, Fang J, Wang C, Han G, Ren W. Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy. Clinics and Research in Hepatology and Gastroenterology 2017;41:635-43. [DOI: 10.1016/j.clinre.2017.03.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
279 Sheraz M, Cheng J, Tang L, Chang J, Guo JT. Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA. J Virol. 2019;93. [PMID: 30867306 DOI: 10.1128/jvi.02230-18] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
280 Wu M, Li J, Yue L, Bai L, Li Y, Chen J, Zhang X, Yuan Z. Establishment of Cre-mediated HBV recombinant cccDNA (rcccDNA) cell line for cccDNA biology and antiviral screening assays. Antiviral Res 2018;152:45-52. [PMID: 29432776 DOI: 10.1016/j.antiviral.2018.02.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
281 Batra A, Clark JR, Kang AK, Ali S, Patel TR, Shlobin NA, Hoffman SC, Lim PH, Orban ZS, Visvabharathy L, Graham EL, Sullivan DP, Muller WA, Chou SH, Ungvári Z, Koralnik IJ, Liotta EM. Persistent viral RNA shedding of SARS-CoV-2 is associated with delirium incidence and six-month mortality in hospitalized COVID-19 patients. Geroscience 2022. [PMID: 35538386 DOI: 10.1007/s11357-022-00561-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
282 Liao H, Li L, Zheng WV, Zou J, Yu G, Si L, Ge F, Zhou T, Ji D, Chen X, Xu D, Cheng G, Liu Y, Chen J, Colangelo L. Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients. Disease Markers 2022;2022:1-13. [DOI: 10.1155/2022/4133283] [Reference Citation Analysis]
283 Baumert TF, Verrier ER, Nassal M, Chung RT, Zeisel MB. Host-targeting agents for treatment of hepatitis B virus infection. Curr Opin Virol. 2015;14:41-46. [PMID: 26262886 DOI: 10.1016/j.coviro.2015.07.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
284 Choi YM, Kim H, Lee SA, Lee SY, Kim BJ. A Telomerase-Derived Peptide Exerts an Anti-Hepatitis B Virus Effect via Mitochondrial DNA Stress-Dependent Type I Interferon Production. Front Immunol 2020;11:652. [PMID: 32508804 DOI: 10.3389/fimmu.2020.00652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
285 Calvo PL, Pinon M, Dell'Olio D, Carpino A, Biasin E, Pizzol A, Catalano S, Peruzzi L, Rigazio C, Cisarò F, Opramolla A, Asaftei SD, Quarello P, Fagioli F. Management of Hepatitis-B Virus Infection in Immunocompromised Children: A Single Center Experience. J Pediatr Gastroenterol Nutr 2021;72:597-602. [PMID: 33399328 DOI: 10.1097/MPG.0000000000003042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
286 Wang Y, Li Y, Zai W, Hu K, Zhu Y, Deng Q, Wu M, Li Y, Chen J, Yuan Z. HBV covalently closed circular DNA minichromosomes in distinct epigenetic transcriptional states differ in their vulnerability to damage. Hepatology 2022;75:1275-88. [PMID: 34779008 DOI: 10.1002/hep.32245] [Reference Citation Analysis]
287 Senaweera S, Du H, Zhang H, Kirby KA, Tedbury PR, Xie J, Sarafianos SG, Wang Z. Discovery of New Small Molecule Hits as Hepatitis B Virus Capsid Assembly Modulators: Structure and Pharmacophore-Based Approaches. Viruses 2021;13:770. [PMID: 33925540 DOI: 10.3390/v13050770] [Reference Citation Analysis]
288 Dandri M, Petersen J. cccDNA Maintenance in Chronic Hepatitis B - Targeting the Matrix of Viral Replication. Infect Drug Resist 2020;13:3873-86. [PMID: 33149632 DOI: 10.2147/IDR.S240472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
289 Dandri M, Bertoletti A, Lütgehetmann M. Innate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition. Semin Immunopathol 2021. [PMID: 34019142 DOI: 10.1007/s00281-021-00864-x] [Reference Citation Analysis]
290 Lucifora J, Salvetti A, Marniquet X, Mailly L, Testoni B, Fusil F, Inchauspé A, Michelet M, Michel ML, Levrero M, Cortez P, Baumert TF, Cosset FL, Challier C, Zoulim F, Durantel D. Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector. Antiviral Res 2017;145:14-9. [PMID: 28709657 DOI: 10.1016/j.antiviral.2017.07.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
291 Nehme Z, Pasquereau S, Herbein G. Control of viral infections by epigenetic-targeted therapy. Clin Epigenetics 2019;11:55. [PMID: 30917875 DOI: 10.1186/s13148-019-0654-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 12.7] [Reference Citation Analysis]
292 Rybicka M, Woziwodzka A, Romanowski T, Stalke P, Dręczewski M, Bielawski KP. Differences in sequences between HBV-relaxed circular DNA and covalently closed circular DNA. Emerg Microbes Infect 2017;6:e55. [PMID: 28634352 DOI: 10.1038/emi.2017.41] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
293 Testoni B, Lebossé F, Scholtes C, Berby F, Miaglia C, Subic M, Loglio A, Facchetti F, Lampertico P, Levrero M, Zoulim F. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. Journal of Hepatology 2019;70:615-25. [DOI: 10.1016/j.jhep.2018.11.030] [Cited by in Crossref: 84] [Cited by in F6Publishing: 82] [Article Influence: 28.0] [Reference Citation Analysis]
294 Honda T, Yamada N, Murayama A, Shiina M, Aly HH, Kato A, Ito T, Ishizu Y, Kuzuya T, Ishigami M, Murakami Y, Tanaka T, Moriishi K, Nishitsuji H, Shimotohno K, Ishikawa T, Fujishiro M, Muramatsu M, Wakita T, Kato T. Amino Acid Polymorphism in Hepatitis B Virus Associated With Functional Cure. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00159-4. [PMID: 34352407 DOI: 10.1016/j.jcmgh.2021.07.013] [Reference Citation Analysis]
295 Tang J, Huber AD, Pineda DL, Boschert KN, Wolf JJ, Kankanala J, Xie J, Sarafianos SG, Wang Z. 5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors. Eur J Med Chem 2019;164:179-92. [PMID: 30594676 DOI: 10.1016/j.ejmech.2018.12.047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
296 Gao Z, Yan L, Li W. A quantitative method for hepatitis B virus covalently closed circular DNA enables distinguishing direct acting antivirals from cytotoxic agents. Antiviral Res 2019;168:197-202. [PMID: 31175920 DOI: 10.1016/j.antiviral.2019.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
297 Zhang D, Wang Y, Zhang HY, Jiao FZ, Zhang WB, Wang LW, Zhang H, Gong ZJ. Histone deacetylases and acetylated histone H3 are involved in the process of hepatitis B virus DNA replication. Life Sci 2019;223:1-8. [PMID: 30862568 DOI: 10.1016/j.lfs.2019.03.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
298 Koike K, Suyama K, Ito H, Itoh H, Sugiura W. Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naïve chronic hepatitis B patients: Non-inferiority of TDF to ETV in CHB. Hepatol Res 2018;48:59-68. [DOI: 10.1111/hepr.12902] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
299 Wei ZQ, Zhang YH, Ke CZ, Chen HX, Ren P, He YL, Hu P, Ma DQ, Luo J, Meng ZJ. Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation. World J Gastroenterol 2017; 23(34): 6252-6260 [PMID: 28974891 DOI: 10.3748/wjg.v23.i34.6252] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
300 Kim GW, Moon JS, Siddiqui A. N6-methyladenosine modification of the 5' epsilon structure of the HBV pregenome RNA regulates its encapsidation by the viral core protein. Proc Natl Acad Sci U S A 2022;119:e2120485119. [PMID: 35135882 DOI: 10.1073/pnas.2120485119] [Reference Citation Analysis]
301 Torres-Cornejo A, Lauer GM. Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines. Pathog Immun 2017;2:102-25. [PMID: 28664194 DOI: 10.20411/pai.v2i1.201] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
302 Zankharia US, Kudchodkar S, Khoshnejad M, Perales-Puchalt A, Choi H, Ho M, Zaidi F, Ugen KE, Kim JJ, Weiner DB, Muthumani K. Neutralization of hepatitis B virus by a novel DNA-encoded monoclonal antibody. Hum Vaccin Immunother 2020;16:2156-64. [PMID: 32463327 DOI: 10.1080/21645515.2020.1763686] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
303 Lu F, Wang J, Chen X, Xu D, Xia N. Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs. Front Med 2017;11:502-8. [PMID: 29170915 DOI: 10.1007/s11684-017-0590-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
304 Pham EA, Perumpail RB, Fram BJ, Glenn JS, Ahmed A, Gish RG. Future Therapy for Hepatitis B Virus: Role of Immunomodulators. Curr Hepatol Rep 2016;15:237-44. [PMID: 27917363 DOI: 10.1007/s11901-016-0315-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
305 Testoni B, Zoulim F. Liver capsule: Validated and potential novel targets to treat hepatitis B virus. Hepatology 2015;62:1619. [PMID: 26340325 DOI: 10.1002/hep.28144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
306 Ligat G, Verrier ER, Nassal M, Baumert TF. Hepatitis B virus-host interactions and novel targets for viral cure. Curr Opin Virol 2021;49:41-51. [PMID: 34029994 DOI: 10.1016/j.coviro.2021.04.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
307 Testoni B, Durantel D, Zoulim F. Novel targets for hepatitis B virus therapy. Liver Int. 2017;37 Suppl 1:33-39. [PMID: 28052622 DOI: 10.1111/liv.13307] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
308 Lecoq L, Wang S, Wiegand T, Bressanelli S, Nassal M, Meier BH, Böckmann A. Solid-state [13C–15N] NMR resonance assignment of hepatitis B virus core protein. Biomol NMR Assign 2018;12:205-14. [DOI: 10.1007/s12104-018-9810-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
309 Xu F, Song H, Xiao Q, Wei Q, Pang X, Gao Y, Tan G. Type-III interferon stimulated gene TRIM31 mutation in an HBV patient blocks its ability in promoting HBx degradation. Virus Res 2022;308:198650. [PMID: 34863820 DOI: 10.1016/j.virusres.2021.198650] [Reference Citation Analysis]
310 Wu SY, Chang YS, Chu TH, Shih C. Persistence of Hepatitis B Virus DNA and the Tempos between Virion Secretion and Genome Maturation in a Mouse Model. J Virol 2019;93:e01001-19. [PMID: 31462567 DOI: 10.1128/JVI.01001-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
311 Verrier ER, Langevin C. Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase (cGAS), a Multifaceted Platform of Intracellular DNA Sensing. Front Immunol 2021;12:637399. [PMID: 33708225 DOI: 10.3389/fimmu.2021.637399] [Reference Citation Analysis]
312 Cheng X, Guan W, Sun S, Li B, Li H, Kang F, Kang J, Yang D, Nassal M, Sun D. Stable Human Hepatoma Cell Lines for Efficient Regulated Expression of Nucleoside/Nucleotide Analog Resistant and Vaccine Escape Hepatitis B Virus Variants and Woolly Monkey Hepatitis B Virus. PLoS One 2015;10:e0145746. [PMID: 26699621 DOI: 10.1371/journal.pone.0145746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
313 Makbul C, Nassal M, Böttcher B. Slowly folding surface extension in the prototypic avian hepatitis B virus capsid governs stability. Elife 2020;9:e57277. [PMID: 32795390 DOI: 10.7554/eLife.57277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
314 Huang W, Du L, Tang H. Hepatitis B virus reactivation: overview and management. Future Virology 2021;16:821-35. [DOI: 10.2217/fvl-2021-0275] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
315 Li F, Cheng L, Murphy CM, Reszka-Blanco NJ, Wu Y, Chi L, Hu J, Su L. Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs. Sci Rep 2016;6:36483. [PMID: 27819342 DOI: 10.1038/srep36483] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
316 Witt-Kehati D, Bitton Alaluf M, Shlomai A. Advances and Challenges in Studying Hepatitis B Virus In Vitro. Viruses. 2016;8. [PMID: 26784218 DOI: 10.3390/v8010021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
317 Akbar SM, Al-Mahtab M, Jahan M, Yoshida O, Hiasa Y. Novel insights into immunotherapy for hepatitis B patients. Expert Rev Gastroenterol Hepatol 2016;10:267-76. [PMID: 26626120 DOI: 10.1586/17474124.2016.1112266] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
318 Wu S, Zhao Q, Zhang P, Kulp J, Hu L, Hwang N, Zhang J, Block TM, Xu X, Du Y, Chang J, Guo JT. Discovery and Mechanistic Study of Benzamide Derivatives That Modulate Hepatitis B Virus Capsid Assembly. J Virol 2017;91:e00519-17. [PMID: 28566379 DOI: 10.1128/JVI.00519-17] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
319 Zehnder B, Urban S, Tu T. A Sensitive and Specific PCR-based Assay to Quantify Hepatitis B Virus Covalently Closed Circular (ccc) DNA while Preserving Cellular DNA. Bio Protoc 2021;11:e3986. [PMID: 34124289 DOI: 10.21769/BioProtoc.3986] [Reference Citation Analysis]
320 Colón-Thillet R, Jerome KR, Stone D. Optimization of AAV vectors to target persistent viral reservoirs. Virol J 2021;18:85. [PMID: 33892762 DOI: 10.1186/s12985-021-01555-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
321 Zaongo SD, Ouyang J, Chen Y, Jiao Y, Wu H, Chen Y. HIV Infection Predisposes to Increased Chances of HBV Infection: Current Understanding of the Mechanisms Favoring HBV Infection at Each Clinical Stage of HIV Infection. Front Immunol 2022;13:853346. [DOI: 10.3389/fimmu.2022.853346] [Reference Citation Analysis]
322 Song H, Xu F, Pang X, Xiao Q, Wei Q, Lei B, Li X, Fan X, Tan G. STAT3-Dependent Gene TRIM5γ Interacts With HBx Through a Zinc Binding Site on the BBox Domain. Front Microbiol 2021;12:663534. [PMID: 34276596 DOI: 10.3389/fmicb.2021.663534] [Reference Citation Analysis]
323 Rodríguez M, Buti M, Esteban R, Lens S, Prieto M, Suárez E, García-Samaniego J. Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). Gastroenterol Hepatol 2020;43:559-87. [PMID: 32778356 DOI: 10.1016/j.gastrohep.2020.03.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
324 Tu T, Zehnder B, Qu B, Ni Y, Main N, Allweiss L, Dandri M, Shackel N, George J, Urban S. A novel method to precisely quantify hepatitis B virus covalently closed circular (ccc)DNA formation and maintenance. Antiviral Res 2020;181:104865. [PMID: 32726641 DOI: 10.1016/j.antiviral.2020.104865] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
325 Wu CCH, Kumar R. Hepatitis B reactivation in patients with hepatitis B core antibody positive and surface antigen negative on immunosuppressants. World J Meta-Anal 2019; 7(5): 209-217 [DOI: 10.13105/wjma.v7.i5.209] [Reference Citation Analysis]
326 Qu B, Brown RJP. Strategies to Inhibit Hepatitis B Virus at the Transcript Level. Viruses 2021;13:1327. [PMID: 34372533 DOI: 10.3390/v13071327] [Reference Citation Analysis]
327 Lythgoe KA, Lumley SF, Pellis L, McKeating JA, Matthews PC. Estimating hepatitis B virus cccDNA persistence in chronic infection. Virus Evol. 2021;7:veaa063. [PMID: 33732502 DOI: 10.1093/ve/veaa063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
328 Wei L, Ploss A. Mechanism of Hepatitis B Virus cccDNA Formation. Viruses 2021;13:1463. [PMID: 34452329 DOI: 10.3390/v13081463] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
329 Rao S, Hossain T, Mahmoudi T. 3D human liver organoids: An in vitro platform to investigate HBV infection, replication and liver tumorigenesis. Cancer Lett 2021;506:35-44. [PMID: 33675983 DOI: 10.1016/j.canlet.2021.02.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
330 Bianca C, Sidhartha E, Tiribelli C, El-Khobar KE, Sukowati CHC. Role of hepatitis B virus in development of hepatocellular carcinoma: Focus on covalently closed circular DNA . World J Hepatol 2022; 14(5): 866-884 [DOI: 10.4254/wjh.v14.i5.866] [Reference Citation Analysis]
331 Chen M, Jagya N, Bansal R, Frelin L, Sällberg M. Prospects and progress of DNA vaccines for treating hepatitis B. Expert Rev Vaccines. 2016;15:629-640. [PMID: 26652035 DOI: 10.1586/14760584.2016.1131615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
332 Yang G, Feng J, Liu Y, Zhao M, Yuan Y, Yuan H, Yun H, Sun M, Bu Y, Liu L, Liu Z, Niu JQ, Yin M, Song X, Miao Z, Lin Z, Zhang X. HAT1 signaling confers to assembly and epigenetic regulation of HBV cccDNA minichromosome. Theranostics 2019;9:7345-58. [PMID: 31695772 DOI: 10.7150/thno.37173] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
333 Wang J, Huang H, Liu Y, Chen R, Yan Y, Shi S, Xi J, Zou J, Yu G, Feng X, Lu F. HBV Genome and Life Cycle. Adv Exp Med Biol 2020;1179:17-37. [PMID: 31741332 DOI: 10.1007/978-981-13-9151-4_2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
334 Sun D, Zhu L, Yao D, Chen L, Fu L, Ouyang L. Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives. European Journal of Medicinal Chemistry 2018;147:205-17. [DOI: 10.1016/j.ejmech.2018.02.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
335 van Campenhout MJH, Rijckborst V, Brouwer WP, van Oord GW, Ferenci P, Tabak F, Akdogan M, Pinarbasi B, Simon K, de Knegt RJ, Boonstra A, Janssen HLA, Hansen BE. Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B. J Viral Hepat 2019;26:1156-63. [PMID: 31135084 DOI: 10.1111/jvh.13117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
336 Zheng J, Ou Z, Xu Y, Xia Z, Lin X, Jin S, Liu Y, Wu J. Hepatitis B virus-specific effector CD8+ T cells are an important determinant of disease prognosis: A meta-analysis. Vaccine 2019;37:2439-46. [PMID: 30935741 DOI: 10.1016/j.vaccine.2019.03.058] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
337 Yu K, Du Z, Li Q, Cheng Q, Huang C, Shi G, Li N. Comparison of non-invasive models for predicting liver damage in chronic hepatitis B patients. Gastroenterol Hepatol 2019;42:281-8. [PMID: 30772087 DOI: 10.1016/j.gastrohep.2018.12.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
338 Luo H, Zhang XX, Cao LH, Tan N, Kang Q, Xi HL, Yu M, Xu XY. Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients. World J Gastroenterol 2019; 25(6): 719-728 [PMID: 30783375 DOI: 10.3748/wjg.v25.i6.719] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
339 Lin J, Gu C, Shen Z, Liu Y, Wang W, Tao S, Cui X, Liu J, Xie Y. Hepatocyte nuclear factor 1α downregulates HBV gene expression and replication by activating the NF-κB signaling pathway. PLoS One 2017;12:e0174017. [PMID: 28319127 DOI: 10.1371/journal.pone.0174017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
340 Zhang L. Autophagy in hepatitis B or C virus infection: An incubator and a potential therapeutic target. Life Sciences 2020;242:117206. [DOI: 10.1016/j.lfs.2019.117206] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
341 Akbar SMF, Al Mahtab M, Khan S, Yoshida O, Aguilar JC, Gerardo GN, Hiasa Y. Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside. Vaccines 2022;10:746. [DOI: 10.3390/vaccines10050746] [Reference Citation Analysis]
342 Marchetti AL, Zhang H, Kim ES, Yu X, Jang S, Wang M, Guo H. Proteomic Analysis of Nuclear HBV rcDNA Associated Proteins Identifies UV-DDB as a Host Factor Involved in cccDNA Formation. J Virol 2021;:JVI0136021. [PMID: 34705558 DOI: 10.1128/JVI.01360-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
343 Yato K, Onodera T, Matsuda M, Moriyama S, Fujimoto A, Watashi K, Aizaki H, Tanaka T, Moriishi K, Nishitsuji H, Shimotohno K, Tamura K, Takahashi Y, Wakita T, Muramatsu M, Kato T, Suzuki R. Identification of Two Critical Neutralizing Epitopes in the Receptor Binding Domain of Hepatitis B Virus preS1. J Virol 2020:JVI. [PMID: 33298539 DOI: 10.1128/JVI.01680-20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
344 Miao J, Gao P, Li Q, He K, Zhang L, Wang J, Huang L. Advances in Nanoparticle Drug Delivery Systems for Anti-Hepatitis B Virus Therapy: A Narrative Review. Int J Mol Sci 2021;22:11227. [PMID: 34681886 DOI: 10.3390/ijms222011227] [Reference Citation Analysis]
345 Thi EP, Dhillon AP, Ardzinski A, Bidirici-Ertekin L, Cobarrubias KD, Cuconati A, Kondratowicz AS, Kwak K, Li AHL, Miller A, Pasetka C, Pei L, Phelps JR, Snead NM, Wang X, Ye X, Sofia MJ, Lee ACH. ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection. ACS Infect Dis 2019;5:725-37. [PMID: 30403127 DOI: 10.1021/acsinfecdis.8b00191] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
346 Ko C, Su J, Festag J, Bester R, Kosinska AD, Protzer U. Intramolecular recombination enables the formation of hepatitis B virus (HBV) cccDNA in mice after HBV genome transfer using recombinant AAV vectors. Antiviral Res 2021;194:105140. [PMID: 34284057 DOI: 10.1016/j.antiviral.2021.105140] [Reference Citation Analysis]
347 Lythgoe KA, Gardner A, Pybus OG, Grove J. Short-Sighted Virus Evolution and a Germline Hypothesis for Chronic Viral Infections. Trends Microbiol 2017;25:336-48. [PMID: 28377208 DOI: 10.1016/j.tim.2017.03.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 6.4] [Reference Citation Analysis]
348 Newton L, Necochea R, Palm D, Taylor J, Barr L, Patel H, Nathan A, Gerrard J, Sylla L, Brown B, Dubé K. Revisiting the ‘sterilising cure’ terminology: a call for more patient-centred perspectives on HIV cure-related research. Journal of Virus Eradication 2019;5:122-4. [DOI: 10.1016/s2055-6640(20)30054-6] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
349 Zhao Z, Feng M, Wan J, Zheng X, Teng C, Xie X, Pan W, Hu B, Huang J, Liu Z, Wu J, Cai S. Research progress of epigallocatechin-3-gallate (EGCG) on anti-pathogenic microbes and immune regulation activities. Food Funct 2021;12:9607-19. [PMID: 34549212 DOI: 10.1039/d1fo01352a] [Reference Citation Analysis]
350 Lamb C, Arbuthnot P. Activating the innate immune response to counter chronic hepatitis B virus infection. Expert Opin Biol Ther 2016;16:1517-27. [PMID: 27603796 DOI: 10.1080/14712598.2016.1233962] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
351 Dandri M, Petersen J. Animal models of HBV infection. Best Pract Res Clin Gastroenterol 2017;31:273-9. [PMID: 28774409 DOI: 10.1016/j.bpg.2017.04.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
352 Hadziyannis E, Laras A. Viral Biomarkers in Chronic HBeAg Negative HBV Infection. Genes (Basel) 2018;9:E469. [PMID: 30262738 DOI: 10.3390/genes9100469] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
353 Tsounis EP, Tourkochristou E, Mouzaki A, Triantos C. Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure. World J Gastroenterol 2021;27:2727-57. [PMID: 34135551 DOI: 10.3748/wjg.v27.i21.2727] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
354 Höner Zu Siederdissen C, Maasoumy B, Cornberg M. New viral biomarkers for Hepatitis B: Are we able to change practice? J Viral Hepat 2018;25:1226-35. [PMID: 30187603 DOI: 10.1111/jvh.12993] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
355 Stadelmayer B, Diederichs A, Chapus F, Rivoire M, Neveu G, Alam A, Fraisse L, Carter K, Testoni B, Zoulim F. Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum. J Hepatol 2020;73:40-51. [PMID: 32087349 DOI: 10.1016/j.jhep.2020.01.028] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
356 Joshi SS, Coffin CS. Hepatitis B virus lymphotropism: emerging details and challenges. Biotechnology and Genetic Engineering Reviews 2018;34:139-51. [DOI: 10.1080/02648725.2018.1474324] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
357 Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yan Z. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver 2020;14:232-47. [PMID: 31158948 DOI: 10.5009/gnl18546] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 22.0] [Reference Citation Analysis]
358 Shih C, Chou S, Yang C, Huang J, Choijilsuren G, Jhou R. Control and Eradication Strategies of Hepatitis B Virus. Trends in Microbiology 2016;24:739-49. [DOI: 10.1016/j.tim.2016.05.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
359 Martinez MG, Boyd A, Combe E, Testoni B, Zoulim F. Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections. J Hepatol 2021;75:706-17. [PMID: 34051332 DOI: 10.1016/j.jhep.2021.05.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
360 Siyahian A, Malik SU, Mushtaq A, Howe CL, Majeed A, Zangeneh T, Iftikhar S, Habib S, Zahid U, Riaz IB, Warraich Z, Faridi W, Anwer F. Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant 2018;24:1483-9. [PMID: 29545185 DOI: 10.1016/j.bbmt.2018.02.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
361 Almeida PH, Matielo CEL, Curvelo LA, Rocco RA, Felga G, Della Guardia B, Boteon YL. Update on the management and treatment of viral hepatitis. World J Gastroenterol 2021; 27(23): 3249-3261 [PMID: 34163109 DOI: 10.3748/wjg.v27.i23.3249] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
362 Lok J, Dusheiko G, Carey I, Agarwal K. Review article: Novel biomarkers in hepatitis B infection. Aliment Pharmacol Ther 2022. [PMID: 35770458 DOI: 10.1111/apt.17105] [Reference Citation Analysis]
363 Nishida Y, Imamura M, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Abe-Chayama H, Hayes CN, Aikata H, Sasaki N, Sekiguchi T, Kinukawa H, Yoshimura T, Chayama K. Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. J Viral Hepat 2021;28:1304-11. [PMID: 34105859 DOI: 10.1111/jvh.13557] [Reference Citation Analysis]
364 Chen Y, Yao Y, Zhao K, Liu C, Yuan Y, Sun H, Huang D, Zheng Y, Zhou Y, Chen J, Wang Y, Wu C, Zhang B, Guan Y, Li F, Pei R, Chen X, James Ou J. DNA Repair Factor Poly(ADP-Ribose) Polymerase 1 Is a Proviral Factor in Hepatitis B Virus Covalently Closed Circular DNA Formation. J Virol. [DOI: 10.1128/jvi.00585-22] [Reference Citation Analysis]
365 Liu S, Xin Y. HBV cccDNA: The Stumbling Block for Treatment of HBV Infection. J Clin Transl Hepatol 2019;7:195-6. [PMID: 31608210 DOI: 10.14218/JCTH.2019.00047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
366 Anderson RT, Lim SG, Mishra P, Josephson F, Donaldson E, Given B, Miller V. Challenges, Considerations, and Principles to Guide Trials of Combination Therapies for Chronic Hepatitis B Virus. Gastroenterology 2019;156:529-533.e4. [DOI: 10.1053/j.gastro.2018.11.062] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
367 Wang X, Wei Z, Jiang Y, Meng Z, Lu M. mTOR Signaling: The Interface Linking Cellular Metabolism and Hepatitis B Virus Replication. Virol Sin 2021. [PMID: 34580816 DOI: 10.1007/s12250-021-00450-3] [Reference Citation Analysis]
368 Yang YC, Chen YH, Kao JH, Ching C, Liu IJ, Wang CC, Tsai CH, Wu FY, Liu CJ, Chen PJ, Chen DS, Yang HC. Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing. Mol Ther Nucleic Acids. 2020;20:480-490. [PMID: 32278307 DOI: 10.1016/j.omtn.2020.03.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
369 Lebossé F, Inchauspé A, Locatelli M, Miaglia C, Diederichs A, Fresquet J, Chapus F, Hamed K, Testoni B, Zoulim F. Quantification and epigenetic evaluation of the residual pool of hepatitis B covalently closed circular DNA in long-term nucleoside analogue-treated patients. Sci Rep 2020;10:21097. [PMID: 33273565 DOI: 10.1038/s41598-020-78001-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
370 Fatehi F, Bingham RJ, Dykeman EC, Patel N, Stockley PG, Twarock R. An Intracellular Model of Hepatitis B Viral Infection: An In Silico Platform for Comparing Therapeutic Strategies. Viruses 2020;13:E11. [PMID: 33374798 DOI: 10.3390/v13010011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
371 Song H, Tan G, Yang Y, Cui A, Li H, Li T, Wu Z, Yang M, Lv G, Chi X, Niu J, Zhu K, Crispe IN, Su L, Tu Z. Hepatitis B Virus-Induced Imbalance of Inflammatory and Antiviral Signaling by Differential Phosphorylation of STAT1 in Human Monocytes. J Immunol. 2019;202:2266-2275. [PMID: 30842274 DOI: 10.4049/jimmunol.1800848] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
372 Soriano V, Barreiro P, Benitez L, Peña JM, de Mendoza C. New antivirals for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs 2017;26:843-51. [DOI: 10.1080/13543784.2017.1333105] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
373 Hoogeveen RC, Robidoux MP, Schwarz T, Heydmann L, Cheney JA, Kvistad D, Aneja J, Melgaço JG, Fernandes CA, Chung RT, Boonstra A, Kim AY, Baumert TF, Timm J, Lewis-Ximenez LL, Tonnerre P, Lauer GM. Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection. Gut 2019;68:893-904. [PMID: 30580250 DOI: 10.1136/gutjnl-2018-316644] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 19.0] [Reference Citation Analysis]
374 Tan G, Song H, Xu F, Cheng G. When Hepatitis B Virus Meets Interferons. Front Microbiol 2018;9:1611. [PMID: 30072974 DOI: 10.3389/fmicb.2018.01611] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
375 Wang ML, Liao J, Ye F, Tao YC, Wu DB, He M, Tang H, Chen EQ. Distribution and factors associated with serum HBV pregenomic RNA levels in Chinese chronic hepatitis B patients. J Med Virol 2021;93:3688-96. [PMID: 32949174 DOI: 10.1002/jmv.26529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
376 Lai CL, Wong DK, Wong GT, Seto WK, Fung J, Yuen MF. Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed. JHEP Rep. 2020;2:100112. [PMID: 32462119 DOI: 10.1016/j.jhepr.2020.100112] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
377 Mitra B, Wang J, Kim ES, Mao R, Dong M, Liu Y, Zhang J, Guo H. Hepatitis B Virus Precore Protein p22 Inhibits Alpha Interferon Signaling by Blocking STAT Nuclear Translocation. J Virol. 2019;93. [PMID: 31019054 DOI: 10.1128/jvi.00196-19] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
378 Ligat G, Goto K, Verrier E, Baumert TF. Targeting Viral cccDNA for Cure of Chronic Hepatitis B. Curr Hepatology Rep 2020;19:235-44. [DOI: 10.1007/s11901-020-00534-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
379 Ning WF, Wang F, Deng HJ, Chen HH. Screening of differentially expressed genes in chronic hepatitis B patients and prediction of related biological pathways. Shijie Huaren Xiaohua Zazhi 2016; 24(16): 2485-2491 [DOI: 10.11569/wcjd.v24.i16.2485] [Reference Citation Analysis]
380 Ren JH, Hu JL, Cheng ST, Yu HB, Wong VKW, Law BYK, Yang YF, Huang Y, Liu Y, Chen WX, Cai XF, Tang H, Hu Y, Zhang WL, Liu X, Long QX, Zhou L, Tao NN, Zhou HZ, Yang QX, Ren F, He L, Gong R, Huang AL, Chen J. SIRT3 restricts hepatitis B virus transcription and replication through epigenetic regulation of covalently closed circular DNA involving suppressor of variegation 3-9 homolog 1 and SET domain containing 1A histone methyltransferases. Hepatology 2018;68:1260-76. [PMID: 29624717 DOI: 10.1002/hep.29912] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 10.5] [Reference Citation Analysis]
381 Pereira-Gómez M, Bou JV, Andreu I, Sanjuán R. Lamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in Patients. PLoS One 2016;11:e0163363. [PMID: 27649318 DOI: 10.1371/journal.pone.0163363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
382 Yuan H, Zhao L, Yuan Y, Yun H, Zheng W, Geng Y, Yang G, Wang Y, Zhao M, Zhang X. HBx represses WDR77 to enhance HBV replication by DDB1-mediated WDR77 degradation in the liver. Theranostics 2021;11:8362-78. [PMID: 34373747 DOI: 10.7150/thno.57531] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
383 Ko C, Michler T, Protzer U. Novel viral and host targets to cure hepatitis B. Current Opinion in Virology 2017;24:38-45. [DOI: 10.1016/j.coviro.2017.03.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
384 Singh P, Kairuz D, Arbuthnot P, Bloom K. Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach. World J Gastroenterol 2021; 27(23): 3182-3207 [PMID: 34163105 DOI: 10.3748/wjg.v27.i23.3182] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
385 Palmer M, Regev A, Lindor K, Avigan MI, Dimick-Santos L, Treem W, Marcinak JF, Lewis JH, Anania FA, Seekins D, Shneider BL, Chalasani N. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Aliment Pharmacol Ther. 2020;51:90-109. [PMID: 31762074 DOI: 10.1111/apt.15579] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
386 Péneau C, Zucman-Rossi J, Nault JC. Genomics of Viral Hepatitis-Associated Liver Tumors. J Clin Med 2021;10:1827. [PMID: 33922394 DOI: 10.3390/jcm10091827] [Reference Citation Analysis]
387 Menéndez-Arias L, Sebastián-Martín A, Álvarez M. Viral reverse transcriptases. Virus Res 2017;234:153-76. [PMID: 28043823 DOI: 10.1016/j.virusres.2016.12.019] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
388 Yu Y, Li S, Liang W. Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets. Emerg Microbes Infect 2018;7:134. [PMID: 30050063 DOI: 10.1038/s41426-018-0137-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
389 de Rocquigny H, Rat V, Pastor F, Darlix JL, Hourioux C, Roingeard P. Phosphorylation of the Arginine-Rich C-Terminal Domains of the Hepatitis B Virus (HBV) Core Protein as a Fine Regulator of the Interaction between HBc and Nucleic Acid. Viruses 2020;12:E738. [PMID: 32650547 DOI: 10.3390/v12070738] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
390 Yao Y, Yang B, Chen Y, Wang H, Hu X, Zhou Y, Gao X, Lu M, Niu J, Wen Z, Wu C, Chen X. RNA-Binding Motif Protein 24 (RBM24) Is Involved in Pregenomic RNA Packaging by Mediating Interaction between Hepatitis B Virus Polymerase and the Epsilon Element. J Virol 2019;93:e02161-18. [PMID: 30626666 DOI: 10.1128/JVI.02161-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
391 Wu W, Wu D, Yan W, Wang Y, You J, Wan X, Xi D, Luo X, Han M, Ning Q. Interferon-Induced Macrophage-Derived Exosomes Mediate Antiviral Activity Against Hepatitis B Virus Through miR-574-5p. J Infect Dis 2021;223:686-98. [PMID: 32663850 DOI: 10.1093/infdis/jiaa399] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
392 Wei L, Cafiero T, Tseng A, Gertje HP, Berneshawi A, Crossland NA, Ploss A. Conversion of hepatitis B virus relaxed circular to covalently closed circular DNA is supported in murine cells. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100534] [Reference Citation Analysis]
393 van Campenhout MJ, Brouwer WP, van Oord GW, Xie Q, Zhang Q, Zhang N, Guo S, Tabak F, Streinu-Cercel A, Wang J, Pas SD, Sonneveld MJ, de Knegt RJ, Boonstra A, Hansen BE, Janssen HL. Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients. Clin Microbiol Infect 2016;22:571.e5-9. [PMID: 26898481 DOI: 10.1016/j.cmi.2016.02.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
394 Li H, Sheng C, Wang S, Yang L, Liang Y, Huang Y, Liu H, Li P, Yang C, Yang X. Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9. Front Cell Infect Microbiol. 2017;7:91. [PMID: 28382278 DOI: 10.3389/fcimb.2017.00091] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
395 Wu YH, Yang Y, Chen CH, Hsiao CJ, Li TN, Liao KJ, Watashi K, Chen BS, Wang LH. Aerobic glycolysis supports hepatitis B virus protein synthesis through interaction between viral surface antigen and pyruvate kinase isoform M2. PLoS Pathog 2021;17:e1008866. [PMID: 33720996 DOI: 10.1371/journal.ppat.1008866] [Reference Citation Analysis]
396 Charre C, Levrero M, Zoulim F, Scholtès C. Non-invasive biomarkers for chronic hepatitis B virus infection management. Antiviral Res 2019;169:104553. [PMID: 31288041 DOI: 10.1016/j.antiviral.2019.104553] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
397 Pollicino T, Caminiti G. HBV-Integration Studies in the Clinic: Role in the Natural History of Infection. Viruses 2021;13:368. [PMID: 33652619 DOI: 10.3390/v13030368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
398 Tan N, Luo H, Kang Q, Pan JL, Cheng R, Xi HL, Chen HY, Han YF, yang YP, Xu XY. Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment. World J Clin Cases 2021; 9(21): 5812-5821 [PMID: 34368300 DOI: 10.12998/wjcc.v9.i21.5812] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
399 Chauhan R, Lingala S, Gadiparthi C, Lahiri N, Mohanty SR, Wu J, Michalak TI, Satapathy SK. Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management. World J Hepatol 2018; 10(3): 352-370 [PMID: 29599899 DOI: 10.4254/wjh.v10.i3.352] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
400 Yang Y, Yan Y, Chen Z, Hu J, Wang K, Tang N, Li X, Zhou Z. Histone Deacetylase Inhibitors Romidepsin and Vorinostat Promote Hepatitis B Virus Replication by Inducing Cell Cycle Arrest. J Clin Transl Hepatol 2021;9:160-8. [PMID: 34007797 DOI: 10.14218/JCTH.2020.00105] [Reference Citation Analysis]
401 Loureiro D, Tout I, Narguet S, Benazzouz SM, Mansouri A, Asselah T. miRNAs as Potential Biomarkers for Viral Hepatitis B and C. Viruses 2020;12:E1440. [PMID: 33327640 DOI: 10.3390/v12121440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
402 Lee S, Goyal A, Perelson AS, Ishida Y, Saito T, Gale M Jr. Suppression of hepatitis B virus through therapeutic activation of RIG-I and IRF3 signaling in hepatocytes. iScience 2021;24:101969. [PMID: 33458618 DOI: 10.1016/j.isci.2020.101969] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
403 Lee YH, Cha HM, Hwang JY, Park SY, Vishakantegowda AG, Imran A, Lee JY, Yi YS, Jun S, Kim GH, Kang HJ, Chung SJ, Kim M, Kim H, Han SB. Sulfamoylbenzamide-based Capsid Assembly Modulators for Selective Inhibition of Hepatitis B Viral Replication. ACS Med Chem Lett 2021;12:242-8. [PMID: 33603970 DOI: 10.1021/acsmedchemlett.0c00606] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
404 Liao Z, Jiang W, Ye L, Li T, Yu X, Liu L. Classification of extrachromosomal circular DNA with a focus on the role of extrachromosomal DNA (ecDNA) in tumor heterogeneity and progression. Biochim Biophys Acta Rev Cancer 2020;1874:188392. [PMID: 32735964 DOI: 10.1016/j.bbcan.2020.188392] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
405 Xu L, Wu Z, Tan S, Wang Z, Lin Q, Li X, Song X, Liu Y, Song Y, Zhang J, Peng J, Gao L, Gong Y, Liang X, Zuo X, Ma C. Tumor suppressor ZHX2 restricts hepatitis B virus replication via epigenetic and non-epigenetic manners. Antiviral Research 2018;153:114-23. [DOI: 10.1016/j.antiviral.2018.03.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
406 Tan M, Ren F, Yang X. Anti-HBV therapeutic potential of small molecule 3,5,6,7,3',4'-Hexamethoxyflavone in vitro and in vivo. Virology 2021;560:66-75. [PMID: 34051476 DOI: 10.1016/j.virol.2021.05.007] [Reference Citation Analysis]
407 Kamiya N, Sugimoto T, Abe-Chayama H, Akiyama R, Tsuboi Y, Mogami A, Imamura M, Hayes CN, Chayama K. Untying relaxed circular DNA of hepatitis B virus by polymerase reaction provides a new option for accurate quantification and visualization of covalently closed circular DNA. J Gen Virol 2022;103. [PMID: 35130138 DOI: 10.1099/jgv.0.001591] [Reference Citation Analysis]
408 Nicolini LA, Orsi A, Tatarelli P, Viscoli C, Icardi G, Sticchi L. A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals. Int J Environ Res Public Health 2019;16:E3307. [PMID: 31505743 DOI: 10.3390/ijerph16183307] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
409 Chabrolles H, Auclair H, Vegna S, Lahlali T, Pons C, Michelet M, Couté Y, Belmudes L, Chadeuf G, Kim Y, Di Bernardo A, Jalaguier P, Cosset FL, Fusil F, Rivoire M, Arnold LD, Lopatin U, Combet C, Zoulim F, Grierson D, Chabot B, Lucifora J, Durantel D, Salvetti A. Hepatitis B virus Core protein nuclear interactome identifies SRSF10 as a host RNA-binding protein restricting HBV RNA production. PLoS Pathog 2020;16:e1008593. [PMID: 33180834 DOI: 10.1371/journal.ppat.1008593] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
410 Lahlali T, Berke JM, Vergauwen K, Foca A, Vandyck K, Pauwels F, Zoulim F, Durantel D. Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle. Antimicrob Agents Chemother 2018;62:e00835-18. [PMID: 30012770 DOI: 10.1128/AAC.00835-18] [Cited by in Crossref: 37] [Cited by in F6Publishing: 18] [Article Influence: 9.3] [Reference Citation Analysis]
411 Jiang R, Wang T, Yao Y, Zhou F, Huang X. Hepatitis B infection and intrahepatic cholestasis of pregnancy: A systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e21416. [PMID: 32756142 DOI: 10.1097/MD.0000000000021416] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
412 Price AA, Grakoui A, Weiss DS. Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense. Trends Microbiol 2016;24:294-306. [PMID: 26852268 DOI: 10.1016/j.tim.2016.01.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
413 Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res. 2016;2:163-186. [PMID: 28042609 DOI: 10.20517/2394-5079.2016.05] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 10.7] [Reference Citation Analysis]
414 Yuan Y, Yuan H, Yang G, Yun H, Zhao M, Liu Z, Zhao L, Geng Y, Liu L, Wang J, Zhang H, Wang Y, Zhang XD. IFN-α confers epigenetic regulation of HBV cccDNA minichromosome by modulating GCN5-mediated succinylation of histone H3K79 to clear HBV cccDNA. Clin Epigenetics 2020;12:135. [PMID: 32894195 DOI: 10.1186/s13148-020-00928-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
415 Cai D, Yan R, Xu JZ, Zhang H, Shen S, Mitra B, Marchetti A, Kim ES, Guo H. Characterization of the Termini of Cytoplasmic Hepatitis B Virus Deproteinated Relaxed Circular DNA. J Virol 2020;95:e00922-20. [PMID: 33055252 DOI: 10.1128/JVI.00922-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
416 Mouzannar K, Fusil F, Lacombe B, Ollivier A, Ménard C, Lotteau V, Cosset FL, Ramière C, André P. Farnesoid X receptor-α is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo. FASEB J 2019;33:2472-83. [PMID: 30307769 DOI: 10.1096/fj.201801181R] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
417 Lin H, Li G, Peng X, Deng A, Ye L, Shi L, Wang T, He J. The Use of CRISPR/Cas9 as a Tool to Study Human Infectious Viruses. Front Cell Infect Microbiol 2021;11:590989. [PMID: 34513721 DOI: 10.3389/fcimb.2021.590989] [Reference Citation Analysis]
418 Hu B, Wang R, Fu J, Su M, Du M, Liu Y, Li H, Wang H, Lu F, Jiang J. Integration of hepatitis B virus S gene impacts on hepatitis B surface antigen levels in patients with antiviral therapy. J Gastroenterol Hepatol 2018;33:1389-96. [PMID: 29266382 DOI: 10.1111/jgh.14075] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
419 van Campenhout MJH, van Bömmel F, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, van Vuuren AJ, Berg T, Hansen BE, Janssen HLA. Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. Hepatology 2018;68:839-47. [PMID: 29514389 DOI: 10.1002/hep.29872] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 11.5] [Reference Citation Analysis]
420 Li FC, Li YK, Fan YC. Biomarkers for hepatitis B virus replication: an overview and a look to the future. Expert Rev Gastroenterol Hepatol 2020;14:1131-9. [PMID: 32887529 DOI: 10.1080/17474124.2020.1815530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
421 European Association for the Study of the Liver. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398. [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021] [Cited by in Crossref: 1805] [Cited by in F6Publishing: 1711] [Article Influence: 361.0] [Reference Citation Analysis]
422 Lucifora J, Pastor F, Charles É, Pons C, Auclair H, Fusil F, Rivoire M, Cosset FL, Durantel D, Salvetti A. Evidence for long-term association of virion-delivered HBV core protein with cccDNA independently of viral protein production. JHEP Rep 2021;3:100330. [PMID: 34409278 DOI: 10.1016/j.jhepr.2021.100330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
423 Tajiri K, Shimizu Y. New horizon for radical cure of chronic hepatitis B virus infection. World J Hepatol 2016; 8(21): 863-873 [PMID: 27478536 DOI: 10.4254/wjh.v8.i21.863] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
424 Yu HB, Cheng ST, Ren F, Chen Y, Shi XF, Wong VKW, Law BYK, Ren JH, Zhong S, Chen WX, Xu HM, Zhang ZZ, Hu JL, Cai XF, Hu Y, Zhang WL, Long QX, He L, Hu ZW, Jiang H, Zhou HZ, Huang AL, Chen J. SIRT7 restricts HBV transcription and replication through catalyzing desuccinylation of histone H3 associated with cccDNA minichromosome. Clin Sci (Lond) 2021;135:1505-22. [PMID: 34128977 DOI: 10.1042/CS20210392] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
425 Qu B, Ni Y, Lempp FA, Vondran FWR, Urban S. T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR. J Virol 2018;92:e01117-18. [PMID: 30232183 DOI: 10.1128/JVI.01117-18] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
426 Hayakawa M, Umeyama H, Iwadate M, Taguchi YH, Yano Y, Honda T, Itami-Matsumoto S, Kozuka R, Enomoto M, Tamori A, Kawada N, Murakami Y. Development of a novel anti-hepatitis B virus agent via Sp1. Sci Rep 2020;10:47. [PMID: 31913341 DOI: 10.1038/s41598-019-56842-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
427 Spyrou E, Smith CI, Ghany MG. Hepatitis B: Current Status of Therapy and Future Therapies. Gastroenterol Clin North Am 2020;49:215-38. [PMID: 32389360 DOI: 10.1016/j.gtc.2020.01.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
428 Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. BMJ. 2020;370:m2200. [PMID: 32873599 DOI: 10.1136/bmj.m2200] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
429 Xia Y, Stadler D, Ko C, Protzer U. Analyses of HBV cccDNA Quantification and Modification. Methods Mol Biol 2017;1540:59-72. [PMID: 27975308 DOI: 10.1007/978-1-4939-6700-1_6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
430 Saeed U, Kim J, Piracha ZZ, Kwon H, Jung J, Chwae YJ, Park S, Shin HJ, Kim K. Parvulin 14 and Parvulin 17 Bind to HBx and cccDNA and Upregulate Hepatitis B Virus Replication from cccDNA to Virion in an HBx-Dependent Manner. J Virol. 2019;93. [PMID: 30567987 DOI: 10.1128/jvi.01840-18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
431 Ahmed Z, Shetty A, Victor DW, Kodali S. Viral hepatitis: A narrative review of hepatitis A–E. World J Meta-Anal 2022; 10(3): 99-121 [DOI: 10.13105/wjma.v10.i3.99] [Reference Citation Analysis]
432 Verrier ER, Yim SA, Heydmann L, El Saghire H, Bach C, Turon-Lagot V, Mailly L, Durand SC, Lucifora J, Durantel D, Pessaux P, Manel N, Hirsch I, Zeisel MB, Pochet N, Schuster C, Baumert TF. Hepatitis B Virus Evasion From Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase Sensing in Human Hepatocytes. Hepatology 2018;68:1695-709. [PMID: 29679386 DOI: 10.1002/hep.30054] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 10.5] [Reference Citation Analysis]
433 Lempp FA, Ni Y, Urban S. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Nat Rev Gastroenterol Hepatol. 2016;13:580-589. [PMID: 27534692 DOI: 10.1038/nrgastro.2016.126] [Cited by in Crossref: 90] [Cited by in F6Publishing: 72] [Article Influence: 15.0] [Reference Citation Analysis]
434 Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf 2021;44:133-65. [PMID: 33141341 DOI: 10.1007/s40264-020-01014-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
435 Allweiss L, Volz T, Giersch K, Kah J, Raffa G, Petersen J, Lohse AW, Beninati C, Pollicino T, Urban S, Lütgehetmann M, Dandri M. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. Gut 2018;67:542-52. [PMID: 28428345 DOI: 10.1136/gutjnl-2016-312162] [Cited by in Crossref: 97] [Cited by in F6Publishing: 84] [Article Influence: 24.3] [Reference Citation Analysis]
436 Laras A, Papatheodoridi M, Panopoulou E, Papatheodoridis GV, Hadziyannis SJ, Hadziyannis E. Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B. Virol J 2022;19. [DOI: 10.1186/s12985-022-01749-7] [Reference Citation Analysis]
437 Yang Y, Zhao X, Wang Z, Shu W, Li L, Li Y, Guo Z, Gao B, Xiong S. Nuclear Sensor Interferon-Inducible Protein 16 Inhibits the Function of Hepatitis B Virus Covalently Closed Circular DNA by Integrating Innate Immune Activation and Epigenetic Suppression. Hepatology 2020;71:1154-69. [PMID: 31402464 DOI: 10.1002/hep.30897] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 13.5] [Reference Citation Analysis]
438 Wang S, Fogeron ML, Schledorn M, Dujardin M, Penzel S, Burdette D, Berke JM, Nassal M, Lecoq L, Meier BH, Böckmann A. Combining Cell-Free Protein Synthesis and NMR Into a Tool to Study Capsid Assembly Modulation. Front Mol Biosci 2019;6:67. [PMID: 31440516 DOI: 10.3389/fmolb.2019.00067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
439 Budzinska MA, Shackel NA, Urban S, Tu T. Cellular Genomic Sites of Hepatitis B Virus DNA Integration. Genes (Basel) 2018;9:E365. [PMID: 30037029 DOI: 10.3390/genes9070365] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
440 Zheng JW, Cao JL, Yuan Q. Sleeping Beauty Transposon-based System forRapid Generation of HBV-replicating Stable Cell Lines. Bio Protoc 2018;8:e2908. [PMID: 34395740 DOI: 10.21769/BioProtoc.2908] [Reference Citation Analysis]
441 Knolle PA, Huang LR, Kosinska A, Wohlleber D, Protzer U. Improving Therapeutic Vaccination against Hepatitis B-Insights from Preclinical Models of Immune Therapy against Persistent Hepatitis B Virus Infection. Vaccines (Basel) 2021;9:1333. [PMID: 34835264 DOI: 10.3390/vaccines9111333] [Reference Citation Analysis]
442 Kaewdech A, Tangkijvanich P, Sripongpun P, Witeerungrot T, Jandee S, Tanaka Y, Piratvisuth T. Hepatitis B surface antigen, core‐related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation. Liver Int 2020;40:2961-71. [DOI: 10.1111/liv.14606] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
443 Liu Y, Xue J, Liao W, Yan H, Liang X. Serum HBV RNA Dynamic and Drug Withdrawal Predictor Value in Patients With Chronic HBV Infection on Long-term Nucleos(t)ide Analogue (NA) Therapy. J Clin Gastroenterol 2020;54:e73-82. [PMID: 32604147 DOI: 10.1097/MCG.0000000000001376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
444 Wu M, Wang C, Shi B, Fang Z, Qin B, Zhou X, Zhang X, Yuan Z. A novel recombinant cccDNA-based mouse model with long term maintenance of rcccDNA and antigenemia. Antiviral Res 2020;180:104826. [PMID: 32502604 DOI: 10.1016/j.antiviral.2020.104826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
445 Ely A, Moyo B, Arbuthnot P. Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus. Mol Ther 2016;24:671-7. [PMID: 26916283 DOI: 10.1038/mt.2016.43] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
446 Liu PJ, Harris JM, Marchi E, D'Arienzo V, Michler T, Wing PAC, Magri A, Ortega-Prieto AM, van de Klundert M, Wettengel J, Durantel D, Dorner M, Klenerman P, Protzer U, Giotis ES, McKeating JA. Hypoxic gene expression in chronic hepatitis B virus infected patients is not observed in state-of-the-art in vitro and mouse infection models. Sci Rep 2020;10:14101. [PMID: 32839523 DOI: 10.1038/s41598-020-70865-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
447 Agrawal B, Kumar R. Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses. World J Gastroenterol 2016; 22(25): 5623-5626 [PMID: 27433078 DOI: 10.3748/wjg.v22.i25.5623] [Reference Citation Analysis]
448 Shi X, Wang X, Xu X, Feng Y, Li S, Feng S, Wang B, Wang S. Impact of HBV replication in peripheral blood mononuclear cell on HBV intrauterine transmission. Front Med. 2017;11:548-553. [PMID: 29170913 DOI: 10.1007/s11684-017-0597-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
449 Iacob DG, Rosca A, Ruta SM. Circulating microRNAs as non-invasive biomarkers for hepatitis B virus liver fibrosis. World J Gastroenterol 2020; 26(11): 1113-1127 [PMID: 32231417 DOI: 10.3748/wjg.v26.i11.1113] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
450 Lindh M, Rydell GE, Larsson SB. Impact of integrated viral DNA on the goal to clear hepatitis B surface antigen with different therapeutic strategies. Curr Opin Virol 2018;30:24-31. [PMID: 29453099 DOI: 10.1016/j.coviro.2018.01.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
451 Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World J Hepatol 2021; 13(9): 1042-1057 [PMID: 34630873 DOI: 10.4254/wjh.v13.i9.1042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
452 Meier-Stephenson V, Bremner WTR, Dalton CS, van Marle G, Coffin CS, Patel TR. Comprehensive Analysis of Hepatitis B Virus Promoter Region Mutations. Viruses 2018;10:E603. [PMID: 30388827 DOI: 10.3390/v10110603] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
453 Chuaypen N, Sriprapun M, Praianantathavorn K, Payungporn S, Wisedopas N, Poovorawan Y, Tangkijvanich P. Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. J Med Virol. 2017;89:130-138. [PMID: 27307409 DOI: 10.1002/jmv.24601] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
454 Guo JT, Guo H. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics. Antiviral Res. 2015;122:91-100. [PMID: 26272257 DOI: 10.1016/j.antiviral.2015.08.005] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 11.9] [Reference Citation Analysis]
455 Kostyusheva A, Kostyushev D, Brezgin S, Volchkova E, Chulanov V. Clinical Implications of Hepatitis B Virus RNA and Covalently Closed Circular DNA in Monitoring Patients with Chronic Hepatitis B Today with a Gaze into the Future: The Field Is Unprepared for a Sterilizing Cure. Genes (Basel) 2018;9:E483. [PMID: 30301171 DOI: 10.3390/genes9100483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
456 Lecoq L, Wang S, Dujardin M, Zimmermann P, Schuster L, Fogeron ML, Briday M, Schledorn M, Wiegand T, Cole L, Montserret R, Bressanelli S, Meier BH, Nassal M, Böckmann A. A pocket-factor-triggered conformational switch in the hepatitis B virus capsid. Proc Natl Acad Sci U S A 2021;118:e2022464118. [PMID: 33879615 DOI: 10.1073/pnas.2022464118] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
457 Liao R, Liu L, Zhou J, Wei X, Huang P. Current Molecular Biology and Therapeutic Strategy Status and Prospects for circRNAs in HBV-Associated Hepatocellular Carcinoma. Front Oncol 2021;11:697747. [PMID: 34277444 DOI: 10.3389/fonc.2021.697747] [Reference Citation Analysis]
458 Luo M, Wu S, Kalkeri R, Ptak RG, Zhou T, Van Mellaert L, Wang C, Dumbre SG, Block T, Groaz E, De Jonghe S, Li Y, Herdewijn P. Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug. J Med Chem 2020;63:13851-60. [PMID: 33191744 DOI: 10.1021/acs.jmedchem.0c01381] [Reference Citation Analysis]
459 Toka B, Koksal AS, Eminler AT, Tozlu M, Uslan MI, Parlak E. Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV Reactivation. Dig Dis Sci 2021;66:2417-26. [PMID: 32729014 DOI: 10.1007/s10620-020-06506-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
460 Chi XM, Wang XM, Wang ZF, Wu RH, Gao XZ, Xu HQ, Ding YH, Niu JQ. Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in chronic hepatitis B. World J Gastroenterol 2021; 27(40): 6927-6938 [PMID: 34790015 DOI: 10.3748/wjg.v27.i40.6927] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
461 Cai H, Liu G, Zhong J, Zheng K, Xiao H, Li C, Song X, Li Y, Xu C, Wu H, He Z, Zhu Q. Immune Checkpoints in Viral Infections. Viruses 2020;12:E1051. [PMID: 32967229 DOI: 10.3390/v12091051] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
462 Qu B, Urban S. Quantification of Hepatitis B Virus Covalently Closed Circular DNA in Infected Cell Culture Models by Quantitative PCR. Bio Protoc 2019;9:e3202. [PMID: 33654998 DOI: 10.21769/BioProtoc.3202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]